https://trial.medpath.com/news/probio-opens-128000-square-foot-gene-therapy-manufacturing-center-in-new-jersey 2025-04-09T16:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/probio-opens-128000-square-foot-gene-therapy-manufacturing-center-in-new-jersey 2025-04-09T16:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/infinitopes-secures-mhra-approval-for-phase-i-iia-trial-of-novel-cancer-vaccine-against-oesophageal-adenocarcinoma 2025-04-09T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infinitopes-secures-mhra-approval-for-phase-i-iia-trial-of-novel-cancer-vaccine-against-oesophageal-adenocarcinoma 2025-04-09T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/nexthera-initiates-phase-1-2a-trial-of-nt-101-eye-drops-for-wet-amd-potentially-eliminating-need-for-injections 2025-04-09T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexthera-initiates-phase-1-2a-trial-of-nt-101-eye-drops-for-wet-amd-potentially-eliminating-need-for-injections 2025-04-09T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-to-present-new-clinical-data-on-permeaderm-for-burn-and-wound-management-at-aba-2025 2025-04-09T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avita-medical-to-present-new-clinical-data-on-permeaderm-for-burn-and-wound-management-at-aba-2025 2025-04-09T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/sinomab-s-sm17-shows-breakthrough-results-in-phase-1b-trial-for-atopic-dermatitis 2025-04-09T14:13:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sinomab-s-sm17-shows-breakthrough-results-in-phase-1b-trial-for-atopic-dermatitis 2025-04-09T14:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/longhorn-vaccines-advances-universal-flu-vaccine-with-broad-cross-species-protection 2025-04-09T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longhorn-vaccines-advances-universal-flu-vaccine-with-broad-cross-species-protection 2025-04-09T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/cepheid-and-oxford-nanopore-partner-to-revolutionize-infectious-disease-sequencing-workflows 2025-04-09T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepheid-and-oxford-nanopore-partner-to-revolutionize-infectious-disease-sequencing-workflows 2025-04-09T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/orthopediatrics-launches-fda-cleared-verteglide-system-for-early-onset-scoliosis-treatment 2025-04-09T10:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orthopediatrics-launches-fda-cleared-verteglide-system-for-early-onset-scoliosis-treatment 2025-04-09T10:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/pridopidine-shows-promise-for-als-subgroups-in-healey-platform-trial 2025-04-09T10:33:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pridopidine-shows-promise-for-als-subgroups-in-healey-platform-trial 2025-04-09T10:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-enrolled-in-nih-funded-expanded-access-program-for-mn-166-in-advanced-als 2025-04-09T10:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-enrolled-in-nih-funded-expanded-access-program-for-mn-166-in-advanced-als 2025-04-09T10:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-and-limmatech-advance-pioneering-shigella-vaccine-into-phase-2-trials 2025-04-09T08:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-and-limmatech-advance-pioneering-shigella-vaccine-into-phase-2-trials 2025-04-09T08:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/cdmo-market-report-key-regulatory-approvals-and-clinical-advances-in-march-april-2025 2025-04-09T08:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdmo-market-report-key-regulatory-approvals-and-clinical-advances-in-march-april-2025 2025-04-09T08:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-first-monkeypox-vaccine-enters-phase-i-clinical-trials-with-diverse-volunteer-cohort 2025-04-09T08:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-first-monkeypox-vaccine-enters-phase-i-clinical-trials-with-diverse-volunteer-cohort 2025-04-09T08:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-invests-1-09-billion-to-expand-glp-1-production-capacity-in-brazil 2025-04-09T07:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-invests-1-09-billion-to-expand-glp-1-production-capacity-in-brazil 2025-04-09T07:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/kymera-therapeutics-appoints-noah-goodman-as-chief-business-officer-to-advance-protein-degradation-platform 2025-04-09T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kymera-therapeutics-appoints-noah-goodman-as-chief-business-officer-to-advance-protein-degradation-platform 2025-04-09T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/phenomix-sciences-launches-clinical-trial-to-predict-patient-response-to-glp-1-obesity-treatments 2025-04-09T05:03:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phenomix-sciences-launches-clinical-trial-to-predict-patient-response-to-glp-1-obesity-treatments 2025-04-09T05:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/2025-pharmaceutical-pipeline-major-patent-expirations-set-to-transform-drug-market-with-generics-and-biosimilars 2025-04-09T05:03:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2025-pharmaceutical-pipeline-major-patent-expirations-set-to-transform-drug-market-with-generics-and-biosimilars 2025-04-09T05:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/scientist-com-launches-clinical-labs-navigator-to-streamline-clinical-trial-management 2025-04-09T03:37:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientist-com-launches-clinical-labs-navigator-to-streamline-clinical-trial-management 2025-04-09T03:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-camizestrant-shows-56-reduction-in-breast-cancer-progression-risk-using-blood-test-guided-treatment 2025-04-09T03:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-camizestrant-shows-56-reduction-in-breast-cancer-progression-risk-using-blood-test-guided-treatment 2025-04-09T03:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/orviglance-shows-superior-liver-lesion-detection-in-phase-ii-study-published-in-investigative-radiology 2025-04-09T02:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orviglance-shows-superior-liver-lesion-detection-in-phase-ii-study-published-in-investigative-radiology 2025-04-09T02:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-cardiovia-s-viaone-system-for-safer-access-to-heart-surface-transforming-cardiac-interventions 2025-04-09T00:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-cardiovia-s-viaone-system-for-safer-access-to-heart-surface-transforming-cardiac-interventions 2025-04-09T00:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-advances-world-s-first-pd-l1-adc-to-phase-2-trial-for-advanced-nsclc-treatment 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-advances-world-s-first-pd-l1-adc-to-phase-2-trial-for-advanced-nsclc-treatment 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-clinical-trial-designs-gain-momentum-as-industry-embraces-efficiency-and-innovation 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-clinical-trial-designs-gain-momentum-as-industry-embraces-efficiency-and-innovation 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-safety-analysis-reveals-distinct-adverse-event-profiles-across-anti-her2-drug-classes-in-breast-cancer-treatment 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-safety-analysis-reveals-distinct-adverse-event-profiles-across-anti-her2-drug-classes-in-breast-cancer-treatment 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vaxess-demonstrates-needle-free-glp-1-patch-achieves-comparable-bioavailability-to-injections 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxess-demonstrates-needle-free-glp-1-patch-achieves-comparable-bioavailability-to-injections 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-genetic-test-prostox-predicts-urinary-side-effects-from-prostate-cancer-radiation-therapy 2025-04-08T23:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-genetic-test-prostox-predicts-urinary-side-effects-from-prostate-cancer-radiation-therapy 2025-04-08T23:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/lifemine-therapeutics-initiates-first-in-human-trial-of-novel-calcineurin-inhibitor-life-001 2025-04-08T23:03:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifemine-therapeutics-initiates-first-in-human-trial-of-novel-calcineurin-inhibitor-life-001 2025-04-08T23:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-drug-compound-prevents-long-covid-symptoms-in-mice-offering-hope-for-first-treatment 2025-04-08T23:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-drug-compound-prevents-long-covid-symptoms-in-mice-offering-hope-for-first-treatment 2025-04-08T23:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-of-55-therapies-advancing-toward-potential-functional-cure-for-chronic-hepatitis-b 2025-04-08T22:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-pipeline-of-55-therapies-advancing-toward-potential-functional-cure-for-chronic-hepatitis-b 2025-04-08T22:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/international-psycho-oncology-society-establishes-first-world-psycho-oncology-day-to-advance-integrated-cancer-care 2025-04-08T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-psycho-oncology-society-establishes-first-world-psycho-oncology-day-to-advance-integrated-cancer-care 2025-04-08T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionova-scientific-partners-with-bionique-testing-laboratories-for-mycoplasma-testing-in-biologics-manufacturing 2025-04-08T21:36:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionova-scientific-partners-with-bionique-testing-laboratories-for-mycoplasma-testing-in-biologics-manufacturing 2025-04-08T21:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-workforce-cuts-lead-to-historic-drop-in-medical-device-approvals 2025-04-08T20:44:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-workforce-cuts-lead-to-historic-drop-in-medical-device-approvals 2025-04-08T20:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-theratechnologies-egrifta-sv-prior-approval-supplement-and-alpha-tau-s-trial-for-recurrent-glioblastoma 2025-04-08T20:44:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-theratechnologies-egrifta-sv-prior-approval-supplement-and-alpha-tau-s-trial-for-recurrent-glioblastoma 2025-04-08T20:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/lipella-completes-enrollment-in-phase-iia-trial-for-novel-oral-lichen-planus-treatment 2025-04-08T20:44:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipella-completes-enrollment-in-phase-iia-trial-for-novel-oral-lichen-planus-treatment 2025-04-08T20:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/als-drug-nu-9-shows-promising-results-for-alzheimer-s-disease-in-animal-study 2025-04-08T20:44:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/als-drug-nu-9-shows-promising-results-for-alzheimer-s-disease-in-animal-study 2025-04-08T20:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/hospital-based-addiction-consultation-significantly-improves-oud-treatment-outcomes-study-shows 2025-04-08T20:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hospital-based-addiction-consultation-significantly-improves-oud-treatment-outcomes-study-shows 2025-04-08T20:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-withdraws-sickle-cell-drug-oxbryta-globally-following-safety-concerns 2025-04-08T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-withdraws-sickle-cell-drug-oxbryta-globally-following-safety-concerns 2025-04-08T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-settles-exparel-patent-litigation-with-fresenius-kabi-securing-market-exclusivity-until-2030 2025-04-08T17:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-biosciences-settles-exparel-patent-litigation-with-fresenius-kabi-securing-market-exclusivity-until-2030 2025-04-08T17:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/toripalimab-induction-therapy-reduces-disease-progression-risk-by-74-in-bulky-stage-iii-nsclc 2025-04-08T16:41:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toripalimab-induction-therapy-reduces-disease-progression-risk-by-74-in-bulky-stage-iii-nsclc 2025-04-08T16:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/bonyf-advances-novel-alginate-organic-denture-fixative-to-phase-3-clinical-development 2025-04-08T16:41:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bonyf-advances-novel-alginate-organic-denture-fixative-to-phase-3-clinical-development 2025-04-08T16:41:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-agitated-solutions-novel-cardiac-contrast-agent-advancing-to-phase-3-trials 2025-04-08T16:40:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-agitated-solutions-novel-cardiac-contrast-agent-advancing-to-phase-3-trials 2025-04-08T16:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-comanche-biopharma-s-cbp-4888-for-preeclampsia-treatment 2025-04-08T16:40:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-designation-to-comanche-biopharma-s-cbp-4888-for-preeclampsia-treatment 2025-04-08T16:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/algernon-pharmaceuticals-secures-european-patent-for-repirinast-in-kidney-disease-treatment 2025-04-08T16:40:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algernon-pharmaceuticals-secures-european-patent-for-repirinast-in-kidney-disease-treatment 2025-04-08T16:40:38+00:00 hourly 0.9 https://trial.medpath.com/news/japan-grants-first-orphan-drug-designation-for-myotonic-dystrophy-type-1-to-avidity-s-del-desiran 2025-04-08T16:40:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-grants-first-orphan-drug-designation-for-myotonic-dystrophy-type-1-to-avidity-s-del-desiran 2025-04-08T16:40:37+00:00 hourly 0.9 https://trial.medpath.com/news/cosmos-health-expands-global-footprint-with-300000-sky-premium-life-launch-in-albania 2025-04-08T16:39:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmos-health-expands-global-footprint-with-300000-sky-premium-life-launch-in-albania 2025-04-08T16:39:17+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-doses-first-patient-in-phase-1-trial-of-rec-3565-for-relapsed-b-cell-lymphomas 2025-04-08T16:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-doses-first-patient-in-phase-1-trial-of-rec-3565-for-relapsed-b-cell-lymphomas 2025-04-08T16:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/science-37-achieves-second-fda-inspection-success-as-top-enroller-in-phase-3-asthma-trial 2025-04-08T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/science-37-achieves-second-fda-inspection-success-as-top-enroller-in-phase-3-asthma-trial 2025-04-08T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/engine-biosciences-and-eddc-form-strategic-partnership-to-develop-precision-cancer-therapies 2025-04-08T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engine-biosciences-and-eddc-form-strategic-partnership-to-develop-precision-cancer-therapies 2025-04-08T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-cbd-extract-may-reduce-autism-symptoms-in-children-and-adolescents 2025-04-08T14:33:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-cbd-extract-may-reduce-autism-symptoms-in-children-and-adolescents 2025-04-08T14:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cytokine-factory-implant-shows-promise-against-hard-to-treat-cancers 2025-04-08T13:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-cytokine-factory-implant-shows-promise-against-hard-to-treat-cancers 2025-04-08T13:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-reports-strong-survival-benefit-in-phase-2-trial-of-bv100-for-carbapenem-resistant-acinetobacter-infections 2025-04-08T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-reports-strong-survival-benefit-in-phase-2-trial-of-bv100-for-carbapenem-resistant-acinetobacter-infections 2025-04-08T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-receives-1-million-milestone-as-takeda-advances-anti-cd83-antibody-mezagitamab-to-phase-3-for-itp 2025-04-08T13:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-receives-1-million-milestone-as-takeda-advances-anti-cd83-antibody-mezagitamab-to-phase-3-for-itp 2025-04-08T13:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-moderna-s-combination-flu-covid-vaccine-amid-increased-regulatory-scrutiny 2025-04-08T13:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-delays-moderna-s-combination-flu-covid-vaccine-amid-increased-regulatory-scrutiny 2025-04-08T13:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/cerevance-s-cvn293-shows-promising-safety-profile-and-brain-penetration-in-phase-1-trial-for-neurodegenerative-diseases 2025-04-08T11:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerevance-s-cvn293-shows-promising-safety-profile-and-brain-penetration-in-phase-1-trial-for-neurodegenerative-diseases 2025-04-08T11:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/ingenix-secures-eur9m-seed-funding-to-revolutionize-clinical-trials-with-ai-simulation 2025-04-08T10:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ingenix-secures-eur9m-seed-funding-to-revolutionize-clinical-trials-with-ai-simulation 2025-04-08T10:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/cytotronics-unveils-neural-application-for-pixel-platform-revolutionizing-drug-discovery-for-neurological-diseases 2025-04-08T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytotronics-unveils-neural-application-for-pixel-platform-revolutionizing-drug-discovery-for-neurological-diseases 2025-04-08T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-october-2025-pdufa-date-for-xspray-pharma-s-resubmitted-dasynoc-application 2025-04-08T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-october-2025-pdufa-date-for-xspray-pharma-s-resubmitted-dasynoc-application 2025-04-08T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/realta-to-present-phase-2-clinical-data-on-novel-anti-inflammatory-therapy-for-newborn-brain-injury-at-pas-2025 2025-04-08T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/realta-to-present-phase-2-clinical-data-on-novel-anti-inflammatory-therapy-for-newborn-brain-injury-at-pas-2025 2025-04-08T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/alzinova-secures-funding-for-phase-ii-alzheimer-s-drug-trial-preparations 2025-04-08T07:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzinova-secures-funding-for-phase-ii-alzheimer-s-drug-trial-preparations 2025-04-08T07:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/precision-for-medicine-and-sophia-genetics-form-strategic-partnership-to-revolutionize-clinical-trials-with-ai-driven-genomic-analysis 2025-04-08T07:33:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-for-medicine-and-sophia-genetics-form-strategic-partnership-to-revolutionize-clinical-trials-with-ai-driven-genomic-analysis 2025-04-08T07:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/diabetes-pipeline-shows-robust-growth-with-200-companies-developing-novel-therapies 2025-04-08T07:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diabetes-pipeline-shows-robust-growth-with-200-companies-developing-novel-therapies 2025-04-08T07:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/enanta-pharmaceuticals-to-present-promising-rsv-antiviral-data-at-major-european-medical-conferences 2025-04-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enanta-pharmaceuticals-to-present-promising-rsv-antiviral-data-at-major-european-medical-conferences 2025-04-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ampreloxetine-shows-promise-for-neurogenic-orthostatic-hypotension-in-msa-patients-without-worsening-supine-hypertension 2025-04-08T04:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ampreloxetine-shows-promise-for-neurogenic-orthostatic-hypotension-in-msa-patients-without-worsening-supine-hypertension 2025-04-08T04:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/uk-invests-ps600-million-in-health-data-research-service-to-accelerate-clinical-trials 2025-04-08T02:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-invests-ps600-million-in-health-data-research-service-to-accelerate-clinical-trials 2025-04-08T02:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-warns-us-price-negotiations-will-impede-research-as-three-glp-1-drugs-face-scrutiny 2025-04-08T02:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-warns-us-price-negotiations-will-impede-research-as-three-glp-1-drugs-face-scrutiny 2025-04-08T02:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/minnesota-developed-synerfuse-implant-for-chronic-back-pain-advances-toward-fda-approval 2025-04-08T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minnesota-developed-synerfuse-implant-for-chronic-back-pain-advances-toward-fda-approval 2025-04-08T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/uk-mhra-approves-trofolastat-first-psma-targeting-agent-for-prostate-cancer-imaging 2025-04-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-mhra-approves-trofolastat-first-psma-targeting-agent-for-prostate-cancer-imaging 2025-04-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-chimeric-autoantibody-receptor-t-cells-show-promise-for-treating-graves-disease 2025-04-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-chimeric-autoantibody-receptor-t-cells-show-promise-for-treating-graves-disease 2025-04-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acrivon-therapeutics-appoints-renowned-oncologist-dr-mansoor-raza-mirza-as-chief-medical-officer-to-lead-clinical-development 2025-04-07T22:35:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acrivon-therapeutics-appoints-renowned-oncologist-dr-mansoor-raza-mirza-as-chief-medical-officer-to-lead-clinical-development 2025-04-07T22:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/ai-discovered-drug-rentosertib-shows-promising-phase-iia-results-for-idiopathic-pulmonary-fibrosis 2025-04-07T22:12:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-discovered-drug-rentosertib-shows-promising-phase-iia-results-for-idiopathic-pulmonary-fibrosis 2025-04-07T22:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/taurx-s-lmtx-shows-promising-results-for-alzheimer-s-treatment-with-potential-to-become-first-oral-disease-modifying-therapy 2025-04-07T20:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taurx-s-lmtx-shows-promising-results-for-alzheimer-s-treatment-with-potential-to-become-first-oral-disease-modifying-therapy 2025-04-07T20:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-imcivree-shows-significant-weight-loss-in-phase-iii-hypothalamic-obesity-trial 2025-04-07T20:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-imcivree-shows-significant-weight-loss-in-phase-iii-hypothalamic-obesity-trial 2025-04-07T20:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-expands-global-cell-therapy-network-with-new-yokohama-facility-and-advanced-single-use-bioreactor-technology 2025-04-07T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-expands-global-cell-therapy-network-with-new-yokohama-facility-and-advanced-single-use-bioreactor-technology 2025-04-07T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/reunion-neuroscience-to-launch-rekindle-phase-2-trial-for-adjustment-disorder-in-cancer-patients-using-psychedelic-therapy 2025-04-07T16:43:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reunion-neuroscience-to-launch-rekindle-phase-2-trial-for-adjustment-disorder-in-cancer-patients-using-psychedelic-therapy 2025-04-07T16:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-s-crexont-shows-significant-sleep-quality-improvements-in-parkinson-s-disease-patients 2025-04-07T16:43:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-s-crexont-shows-significant-sleep-quality-improvements-in-parkinson-s-disease-patients 2025-04-07T16:43:20+00:00 hourly 0.9 https://trial.medpath.com/news/nih-breakthrough-personalized-immunotherapy-shows-promise-against-gastrointestinal-cancers 2025-04-07T16:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-breakthrough-personalized-immunotherapy-shows-promise-against-gastrointestinal-cancers 2025-04-07T16:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-icu-medical-s-precision-iv-pumps-expanding-infusion-therapy-capabilities 2025-04-07T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-icu-medical-s-precision-iv-pumps-expanding-infusion-therapy-capabilities 2025-04-07T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-fast-tracks-sildenafil-cream-launch-with-dual-market-strategy-for-women-s-health 2025-04-07T16:40:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dare-bioscience-fast-tracks-sildenafil-cream-launch-with-dual-market-strategy-for-women-s-health 2025-04-07T16:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-avenacy-s-propofol-injectable-emulsion-as-generic-alternative-to-diprivan 2025-04-07T16:39:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-avenacy-s-propofol-injectable-emulsion-as-generic-alternative-to-diprivan 2025-04-07T16:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/nordic-pharma-s-canalicular-gel-lacrifill-receives-ce-mark-for-dry-eye-disease-treatment 2025-04-07T16:39:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nordic-pharma-s-canalicular-gel-lacrifill-receives-ce-mark-for-dry-eye-disease-treatment 2025-04-07T16:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-s-imcivree-shows-significant-weight-loss-in-patients-with-hypothalamic-obesity 2025-04-07T16:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-s-imcivree-shows-significant-weight-loss-in-patients-with-hypothalamic-obesity 2025-04-07T16:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-transcriptomics-reveals-new-therapeutic-targets-for-head-and-neck-cancer-immunotherapy 2025-04-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spatial-transcriptomics-reveals-new-therapeutic-targets-for-head-and-neck-cancer-immunotherapy 2025-04-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ipl344-shows-promising-results-in-slowing-als-progression-in-phase-2a-trial 2025-04-07T14:40:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipl344-shows-promising-results-in-slowing-als-progression-in-phase-2a-trial 2025-04-07T14:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/adhd-medications-show-minimal-cardiovascular-effects-in-comprehensive-analysis 2025-04-07T14:40:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adhd-medications-show-minimal-cardiovascular-effects-in-comprehensive-analysis 2025-04-07T14:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/lexeo-therapeutics-partners-with-investors-to-launch-40m-rna-cardiac-therapeutics-spinout 2025-04-07T14:18:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexeo-therapeutics-partners-with-investors-to-launch-40m-rna-cardiac-therapeutics-spinout 2025-04-07T14:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-teva-s-application-for-ajovy-in-pediatric-migraine-prevention-potentially-first-cgrp-antagonist-for-children 2025-04-07T14:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-teva-s-application-for-ajovy-in-pediatric-migraine-prevention-potentially-first-cgrp-antagonist-for-children 2025-04-07T14:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-secures-168-million-in-funding-to-advance-precision-medicine-platform 2025-04-07T13:12:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-secures-168-million-in-funding-to-advance-precision-medicine-platform 2025-04-07T13:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/curevac-advances-novel-mrna-immunotherapy-for-squamous-non-small-cell-lung-cancer-with-fda-ind-clearance 2025-04-07T13:11:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curevac-advances-novel-mrna-immunotherapy-for-squamous-non-small-cell-lung-cancer-with-fda-ind-clearance 2025-04-07T13:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/erbc-and-menarini-biotech-form-strategic-alliance-to-accelerate-biopharmaceutical-development 2025-04-07T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erbc-and-menarini-biotech-form-strategic-alliance-to-accelerate-biopharmaceutical-development 2025-04-07T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-leadership-shuffle-continues-as-industry-navigates-transformation-in-q2-2025 2025-04-07T10:18:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-leadership-shuffle-continues-as-industry-navigates-transformation-in-q2-2025 2025-04-07T10:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/first-real-world-data-for-leqembi-reveals-implementation-challenges-in-alzheimer-s-treatment 2025-04-07T09:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-real-world-data-for-leqembi-reveals-implementation-challenges-in-alzheimer-s-treatment 2025-04-07T09:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-expands-neurodegenerative-disease-portfolio-with-2-5b-abl-bio-partnership 2025-04-07T08:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-expands-neurodegenerative-disease-portfolio-with-2-5b-abl-bio-partnership 2025-04-07T08:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-launches-fexuclue-in-india-a-novel-treatment-for-erosive-esophagitis 2025-04-07T08:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-launches-fexuclue-in-india-a-novel-treatment-for-erosive-esophagitis 2025-04-07T08:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-international-s-blood-test-achieves-91-4-accuracy-in-detecting-oesophageal-cancer 2025-04-07T07:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomics-international-s-blood-test-achieves-91-4-accuracy-in-detecting-oesophageal-cancer 2025-04-07T07:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/neurelis-to-present-new-data-on-diazepam-nasal-spray-for-seizure-management-at-aan-annual-meeting 2025-04-07T05:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurelis-to-present-new-data-on-diazepam-nasal-spray-for-seizure-management-at-aan-annual-meeting 2025-04-07T05:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/specialty-pharmacists-drive-significant-improvements-in-non-ms-neurology-care-study-shows 2025-04-07T03:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/specialty-pharmacists-drive-significant-improvements-in-non-ms-neurology-care-study-shows 2025-04-07T03:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-abl-bio-partner-on-ps2-billion-deal-to-overcome-blood-brain-barrier-in-neurodegenerative-disease-treatment 2025-04-07T02:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-abl-bio-partner-on-ps2-billion-deal-to-overcome-blood-brain-barrier-in-neurodegenerative-disease-treatment 2025-04-07T02:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-first-clinical-trial-of-moderna-s-mrna-vaccine-against-deadly-nipah-virus 2025-04-07T01:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-launches-first-clinical-trial-of-moderna-s-mrna-vaccine-against-deadly-nipah-virus 2025-04-07T01:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-insomnia-drug-suvorexant-shows-promise-in-reducing-alzheimer-s-related-proteins 2025-04-07T01:34:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-insomnia-drug-suvorexant-shows-promise-in-reducing-alzheimer-s-related-proteins 2025-04-07T01:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/luye-pharma-launches-erzofri-single-dose-initiation-long-acting-injectable-for-schizophrenia-treatment 2025-04-06T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luye-pharma-launches-erzofri-single-dose-initiation-long-acting-injectable-for-schizophrenia-treatment 2025-04-06T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/china-advances-rice-derived-human-serum-albumin-to-new-drug-approval-stage 2025-04-06T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-advances-rice-derived-human-serum-albumin-to-new-drug-approval-stage 2025-04-06T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/once-nightly-sodium-oxybate-shows-safety-profile-in-narcolepsy-patients-with-sleep-apnea-concerns 2025-04-06T10:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/once-nightly-sodium-oxybate-shows-safety-profile-in-narcolepsy-patients-with-sleep-apnea-concerns 2025-04-06T10:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/climate-change-and-neurological-health-expert-highlights-critical-connections-and-action-steps 2025-04-06T03:02:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/climate-change-and-neurological-health-expert-highlights-critical-connections-and-action-steps 2025-04-06T03:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapies-show-promise-for-chronic-spontaneous-urticaria-with-complete-response-rates-exceeding-30 2025-04-06T02:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapies-show-promise-for-chronic-spontaneous-urticaria-with-complete-response-rates-exceeding-30 2025-04-06T02:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/gene-editing-breakthrough-david-liu-s-base-and-prime-editing-technologies-transform-treatment-of-genetic-diseases 2025-04-06T01:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-editing-breakthrough-david-liu-s-base-and-prime-editing-technologies-transform-treatment-of-genetic-diseases 2025-04-06T01:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-scientist-dr-daniel-drucker-wins-breakthrough-prize-for-glp-1-hormone-discovery-behind-ozempic-and-mounjaro 2025-04-06T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-scientist-dr-daniel-drucker-wins-breakthrough-prize-for-glp-1-hormone-discovery-behind-ozempic-and-mounjaro 2025-04-06T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsy-drug-ezogabine-shows-promise-as-novel-depression-treatment-by-targeting-brain-potassium-channels 2025-04-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epilepsy-drug-ezogabine-shows-promise-as-novel-depression-treatment-by-targeting-brain-potassium-channels 2025-04-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arizona-advances-bill-for-10m-ibogaine-clinical-trials-to-treat-ptsd-and-neurological-disorders 2025-04-05T23:02:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arizona-advances-bill-for-10m-ibogaine-clinical-trials-to-treat-ptsd-and-neurological-disorders 2025-04-05T23:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/incog-biopharma-services-announces-major-facility-and-capacity-expansion-for-2025 2025-04-05T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incog-biopharma-services-announces-major-facility-and-capacity-expansion-for-2025 2025-04-05T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/bioskryb-genomics-forms-strategic-partnerships-to-revolutionize-single-cell-multi-omics-analysis 2025-04-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioskryb-genomics-forms-strategic-partnerships-to-revolutionize-single-cell-multi-omics-analysis 2025-04-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-therapeutics-secures-2-1-million-in-financing-to-advance-immune-oncology-pipeline 2025-04-05T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptevo-therapeutics-secures-2-1-million-in-financing-to-advance-immune-oncology-pipeline 2025-04-05T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-gene-therapies-evolving-beyond-viral-vectors-towards-more-affordable-sustainable-solutions 2025-04-05T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-gene-therapies-evolving-beyond-viral-vectors-towards-more-affordable-sustainable-solutions 2025-04-05T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-no-benefit-in-pausing-btk-inhibitors-during-covid-19-vaccination-for-cll-patients 2025-04-05T14:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-no-benefit-in-pausing-btk-inhibitors-during-covid-19-vaccination-for-cll-patients 2025-04-05T14:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/statins-show-promise-in-slowing-alzheimer-s-cognitive-decline-large-scale-studies-suggest 2025-04-05T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/statins-show-promise-in-slowing-alzheimer-s-cognitive-decline-large-scale-studies-suggest 2025-04-05T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-questions-roche-on-high-pricing-of-sma-drug-risdiplam-in-india 2025-04-05T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-questions-roche-on-high-pricing-of-sma-drug-risdiplam-in-india 2025-04-05T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-aurobindo-pharma-s-dyrupeg-new-pegfilgrastim-biosimilar-for-chemotherapy-patients 2025-04-05T10:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-aurobindo-pharma-s-dyrupeg-new-pegfilgrastim-biosimilar-for-chemotherapy-patients 2025-04-05T10:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-milestone-pharmaceuticals-etripamil-nasal-spray 2025-04-05T07:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-milestone-pharmaceuticals-etripamil-nasal-spray 2025-04-05T07:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-in-alzheimer-s-disease-mayo-clinic-expert-outlines-future-of-targeted-treatments 2025-04-05T07:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-in-alzheimer-s-disease-mayo-clinic-expert-outlines-future-of-targeted-treatments 2025-04-05T07:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-halts-medicare-and-medicaid-coverage-for-anti-obesity-medications 2025-04-05T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-halts-medicare-and-medicaid-coverage-for-anti-obesity-medications 2025-04-05T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/antag-therapeutics-launches-first-in-human-trial-of-novel-gipr-antagonist-for-obesity-treatment 2025-04-05T02:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antag-therapeutics-launches-first-in-human-trial-of-novel-gipr-antagonist-for-obesity-treatment 2025-04-05T02:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-appoints-dr-sanjay-keswani-as-new-chief-medical-officer 2025-04-05T02:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-appoints-dr-sanjay-keswani-as-new-chief-medical-officer 2025-04-05T02:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-drug-use-rapidly-declines-following-withdrawal-of-fda-accelerated-approval 2025-04-05T01:35:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-drug-use-rapidly-declines-following-withdrawal-of-fda-accelerated-approval 2025-04-05T01:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-drug-studies-due-to-data-falsification-by-indian-cro-raptim-research 2025-04-05T01:35:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-drug-studies-due-to-data-falsification-by-indian-cro-raptim-research 2025-04-05T01:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-to-present-promising-phase-2b-data-for-novel-als-drug-primec-at-aan-meeting 2025-04-04T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosense-to-present-promising-phase-2b-data-for-novel-als-drug-primec-at-aan-meeting 2025-04-04T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-workforce-reduction-creates-new-challenges-for-drug-development-programs 2025-04-04T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-workforce-reduction-creates-new-challenges-for-drug-development-programs 2025-04-04T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-designation-to-neo100-for-aggressive-childhood-brain-cancer 2025-04-04T22:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-designation-to-neo100-for-aggressive-childhood-brain-cancer 2025-04-04T22:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/tr1x-secures-8-million-cirm-grant-to-advance-novel-cell-therapy-for-graft-versus-host-disease 2025-04-04T19:38:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tr1x-secures-8-million-cirm-grant-to-advance-novel-cell-therapy-for-graft-versus-host-disease 2025-04-04T19:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-arv-102-shows-promising-brain-penetration-and-lrrk2-reduction-in-first-in-human-parkinson-s-trial 2025-04-04T19:38:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arvinas-arv-102-shows-promising-brain-penetration-and-lrrk2-reduction-in-first-in-human-parkinson-s-trial 2025-04-04T19:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nk-cell-therapy-with-bispecific-antibody-shows-93-response-rate-in-refractory-lymphoma 2025-04-04T19:38:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nk-cell-therapy-with-bispecific-antibody-shows-93-response-rate-in-refractory-lymphoma 2025-04-04T19:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-licenses-nurix-s-novel-transcription-factor-program-for-autoimmune-disease-treatment 2025-04-04T16:38:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-licenses-nurix-s-novel-transcription-factor-program-for-autoimmune-disease-treatment 2025-04-04T16:38:54+00:00 hourly 0.9 https://trial.medpath.com/news/tremfya-becomes-first-il-23-inhibitor-to-reduce-structural-damage-in-psoriatic-arthritis 2025-04-04T16:38:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tremfya-becomes-first-il-23-inhibitor-to-reduce-structural-damage-in-psoriatic-arthritis 2025-04-04T16:38:12+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-cathay-capital-launch-275m-fund-for-clinical-stage-drug-innovation-in-china 2025-04-04T16:36:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-and-cathay-capital-launch-275m-fund-for-clinical-stage-drug-innovation-in-china 2025-04-04T16:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/former-acting-fda-commissioner-delayed-novavax-vaccine-approval-raising-regulatory-concerns 2025-04-04T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-acting-fda-commissioner-delayed-novavax-vaccine-approval-raising-regulatory-concerns 2025-04-04T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-launches-cohealyx-new-collagen-based-dermal-matrix-accelerates-wound-healing 2025-04-04T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avita-medical-launches-cohealyx-new-collagen-based-dermal-matrix-accelerates-wound-healing 2025-04-04T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/gland-pharma-secures-usfda-approval-for-acetaminophen-injection-for-pain-management 2025-04-04T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gland-pharma-secures-usfda-approval-for-acetaminophen-injection-for-pain-management 2025-04-04T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/orthocell-secures-fda-clearance-for-remplir-nerve-repair-device-targeting-1-6-billion-us-market 2025-04-04T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orthocell-secures-fda-clearance-for-remplir-nerve-repair-device-targeting-1-6-billion-us-market 2025-04-04T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-secures-eu-approval-for-datroway-in-breast-cancer-treatment 2025-04-04T11:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-secures-eu-approval-for-datroway-in-breast-cancer-treatment 2025-04-04T11:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/vividion-therapeutics-initiates-phase-i-trial-of-novel-ras-pi3ka-inhibitor-for-advanced-solid-tumors 2025-04-04T11:02:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vividion-therapeutics-initiates-phase-i-trial-of-novel-ras-pi3ka-inhibitor-for-advanced-solid-tumors 2025-04-04T11:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-first-anti-viral-drug-trial-for-long-covid-treatment 2025-04-04T10:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-first-anti-viral-drug-trial-for-long-covid-treatment 2025-04-04T10:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-advances-novel-gene-therapy-for-knee-osteoarthritis-with-first-patient-dosed-in-phase-2-trial 2025-04-04T10:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-biosciences-advances-novel-gene-therapy-for-knee-osteoarthritis-with-first-patient-dosed-in-phase-2-trial 2025-04-04T10:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/accustem-s-msc-blood-test-set-to-transform-lung-cancer-screening-in-the-us 2025-04-04T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accustem-s-msc-blood-test-set-to-transform-lung-cancer-screening-in-the-us 2025-04-04T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-launches-novocare-r-pharmacy-offering-authentic-wegovy-r-at-499-monthly 2025-04-04T03:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-launches-novocare-r-pharmacy-offering-authentic-wegovy-r-at-499-monthly 2025-04-04T03:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/patient-reported-physical-function-predicts-daratumumab-efficacy-in-multiple-myeloma-patients 2025-04-04T02:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-reported-physical-function-predicts-daratumumab-efficacy-in-multiple-myeloma-patients 2025-04-04T02:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/new-six-month-bpalm-regimen-shows-promise-for-drug-resistant-tb-patients-in-india 2025-04-04T01:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-six-month-bpalm-regimen-shows-promise-for-drug-resistant-tb-patients-in-india 2025-04-04T01:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-trial-demonstrates-safety-of-targeted-therapy-for-deadly-childhood-brain-tumor-dipg 2025-04-04T01:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-i-trial-demonstrates-safety-of-targeted-therapy-for-deadly-childhood-brain-tumor-dipg 2025-04-04T01:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/nih-backed-ai-tool-reduces-hospital-readmissions-for-opioid-use-disorder-by-47 2025-04-04T01:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-backed-ai-tool-reduces-hospital-readmissions-for-opioid-use-disorder-by-47 2025-04-04T01:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/3d-cell-culture-market-set-to-reach-3-48-billion-by-2028-as-pharma-industry-embraces-advanced-in-vitro-models 2025-04-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-cell-culture-market-set-to-reach-3-48-billion-by-2028-as-pharma-industry-embraces-advanced-in-vitro-models 2025-04-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aiml-secures-2-17-million-in-oversubscribed-private-placement-for-ai-healthcare-innovations 2025-04-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aiml-secures-2-17-million-in-oversubscribed-private-placement-for-ai-healthcare-innovations 2025-04-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-biotech-firms-surge-in-global-oncology-licensing-deals-commanding-30-billion-in-2024 2025-04-03T23:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-biotech-firms-surge-in-global-oncology-licensing-deals-commanding-30-billion-in-2024 2025-04-03T23:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/siemens-acquires-dotmatics-for-5-1-billion-to-enhance-ai-capabilities-in-life-sciences 2025-04-03T22:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/siemens-acquires-dotmatics-for-5-1-billion-to-enhance-ai-capabilities-in-life-sciences 2025-04-03T22:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-therapeutics-faces-regulatory-and-safety-setbacks-across-multiple-drug-programs 2025-04-03T22:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edgewise-therapeutics-faces-regulatory-and-safety-setbacks-across-multiple-drug-programs 2025-04-03T22:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/uplizna-becomes-first-fda-approved-treatment-for-igg4-related-disease-reducing-flare-risk-by-87 2025-04-03T22:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uplizna-becomes-first-fda-approved-treatment-for-igg4-related-disease-reducing-flare-risk-by-87 2025-04-03T22:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-histotripsy-cancer-treatment-trials-to-begin-in-singapore-by-2025 2025-04-03T22:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-histotripsy-cancer-treatment-trials-to-begin-in-singapore-by-2025 2025-04-03T22:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/brca2-mechanism-reveals-why-parp-inhibitors-work-in-only-some-cancer-patients 2025-04-03T20:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brca2-mechanism-reveals-why-parp-inhibitors-work-in-only-some-cancer-patients 2025-04-03T20:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-discontinues-tigit-inhibitor-ociperlimab-after-phase-iii-trial-failure-prediction 2025-04-03T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-discontinues-tigit-inhibitor-ociperlimab-after-phase-iii-trial-failure-prediction 2025-04-03T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/pharmamar-expands-global-reach-of-zepzelca-with-argentina-approval-and-merck-partnership-for-japan 2025-04-03T19:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmamar-expands-global-reach-of-zepzelca-with-argentina-approval-and-merck-partnership-for-japan 2025-04-03T19:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/onesource-specialty-pharma-positions-for-major-growth-as-semaglutide-patent-expires-in-2026 2025-04-03T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onesource-specialty-pharma-positions-for-major-growth-as-semaglutide-patent-expires-in-2026 2025-04-03T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/domain-therapeutics-to-showcase-novel-gpcr-targeting-oncology-programs-at-aacr-2025 2025-04-03T17:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/domain-therapeutics-to-showcase-novel-gpcr-targeting-oncology-programs-at-aacr-2025 2025-04-03T17:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/buntanetap-shows-promise-for-parkinson-s-patients-with-mild-dementia-in-phase-iii-trial 2025-04-03T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/buntanetap-shows-promise-for-parkinson-s-patients-with-mild-dementia-in-phase-iii-trial 2025-04-03T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-minovia-s-ind-for-phase-ii-trial-of-novel-mitochondrial-therapy-in-fatal-pediatric-disease 2025-04-03T16:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-minovia-s-ind-for-phase-ii-trial-of-novel-mitochondrial-therapy-in-fatal-pediatric-disease 2025-04-03T16:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/ku-cancer-center-and-va-partnership-expands-early-phase-clinical-trial-access-for-veterans 2025-04-03T16:35:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ku-cancer-center-and-va-partnership-expands-early-phase-clinical-trial-access-for-veterans 2025-04-03T16:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/blossomhill-therapeutics-to-present-novel-omni-egfr-inhibitor-bh-30643-at-aacr-2025-for-nsclc-treatment 2025-04-03T16:34:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blossomhill-therapeutics-to-present-novel-omni-egfr-inhibitor-bh-30643-at-aacr-2025-for-nsclc-treatment 2025-04-03T16:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/virtual-reality-shows-promise-as-non-opioid-pain-management-for-cancer-patients 2025-04-03T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virtual-reality-shows-promise-as-non-opioid-pain-management-for-cancer-patients 2025-04-03T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/plex-research-and-ginkgo-bioworks-partner-to-accelerate-drug-repurposing-through-ai-powered-analysis 2025-04-03T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plex-research-and-ginkgo-bioworks-partner-to-accelerate-drug-repurposing-through-ai-powered-analysis 2025-04-03T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/variant-secures-ema-endorsement-for-var002-gene-therapy-targeting-inherited-retinal-dystrophies 2025-04-03T16:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/variant-secures-ema-endorsement-for-var002-gene-therapy-targeting-inherited-retinal-dystrophies 2025-04-03T16:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/meitheal-pharmaceuticals-launches-generic-liraglutide-amid-ongoing-victoza-shortage 2025-04-03T16:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meitheal-pharmaceuticals-launches-generic-liraglutide-amid-ongoing-victoza-shortage 2025-04-03T16:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-receives-fda-approval-for-pantoprazole-sodium-injection-to-treat-gerd 2025-04-03T16:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-receives-fda-approval-for-pantoprazole-sodium-injection-to-treat-gerd 2025-04-03T16:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-licenses-sangamo-s-blood-brain-barrier-capsid-technology-in-1-4b-cns-deal 2025-04-03T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-licenses-sangamo-s-blood-brain-barrier-capsid-technology-in-1-4b-cns-deal 2025-04-03T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-discontinues-ociperlimab-development-after-failed-phase-iii-lung-cancer-trial 2025-04-03T14:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-discontinues-ociperlimab-development-after-failed-phase-iii-lung-cancer-trial 2025-04-03T14:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/lumen-bioscience-s-oral-biologic-lmn-201-achieves-100-clinical-cure-rate-for-c-difficile-infection-in-preliminary-trial 2025-04-03T13:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumen-bioscience-s-oral-biologic-lmn-201-achieves-100-clinical-cure-rate-for-c-difficile-infection-in-preliminary-trial 2025-04-03T13:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/brain-implant-breakthrough-enables-real-time-speech-for-stroke-survivor-after-18-years 2025-04-03T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-implant-breakthrough-enables-real-time-speech-for-stroke-survivor-after-18-years 2025-04-03T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-and-roche-temporarily-halt-elevidys-trials-in-europe-following-patient-death 2025-04-03T13:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-and-roche-temporarily-halt-elevidys-trials-in-europe-following-patient-death 2025-04-03T13:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/roche-advances-parkinson-s-disease-research-with-novel-assessment-methods-and-digital-health-technologies 2025-04-03T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-advances-parkinson-s-disease-research-with-novel-assessment-methods-and-digital-health-technologies 2025-04-03T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-expression-signature-predicts-immunotherapy-response-across-cancer-types 2025-04-03T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gene-expression-signature-predicts-immunotherapy-response-across-cancer-types 2025-04-03T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/vizgen-settles-litigation-with-10x-genomics-and-harvard-secures-future-for-merfish-technology 2025-04-03T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vizgen-settles-litigation-with-10x-genomics-and-harvard-secures-future-for-merfish-technology 2025-04-03T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-holdings-makes-landmark-investment-in-fungal-biotech-leader-sylvan-to-accelerate-sustainable-solutions 2025-04-03T11:03:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-holdings-makes-landmark-investment-in-fungal-biotech-leader-sylvan-to-accelerate-sustainable-solutions 2025-04-03T11:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-to-acquire-allakos-for-0-33-per-share-in-strategic-biotech-deal 2025-04-03T11:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concentra-biosciences-to-acquire-allakos-for-0-33-per-share-in-strategic-biotech-deal 2025-04-03T11:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-sanofi-s-rilzabrutinib-for-two-rare-diseases 2025-04-03T10:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-sanofi-s-rilzabrutinib-for-two-rare-diseases 2025-04-03T10:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-resvita-bio-s-rvb-003-for-netherton-syndrome 2025-04-03T08:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-resvita-bio-s-rvb-003-for-netherton-syndrome 2025-04-03T08:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/linusbio-and-autism-speaks-join-forces-to-accelerate-early-autism-diagnosis-through-hair-biomarker-test 2025-04-03T08:03:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/linusbio-and-autism-speaks-join-forces-to-accelerate-early-autism-diagnosis-through-hair-biomarker-test 2025-04-03T08:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/immucell-initiates-investigational-use-of-re-tain-for-subclinical-mastitis-in-dairy-cows 2025-04-03T07:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immucell-initiates-investigational-use-of-re-tain-for-subclinical-mastitis-in-dairy-cows 2025-04-03T07:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-groundbreaking-ai-surgical-guidance-platforms-from-proprio-and-medivis 2025-04-03T07:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-groundbreaking-ai-surgical-guidance-platforms-from-proprio-and-medivis 2025-04-03T07:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/resmed-launches-nightowl-fda-cleared-home-sleep-apnea-test-now-available-across-us 2025-04-03T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resmed-launches-nightowl-fda-cleared-home-sleep-apnea-test-now-available-across-us 2025-04-03T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/akamis-bio-initiates-phase-1b-fortress-trial-of-ng-350a-for-locally-advanced-rectal-cancer 2025-04-03T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akamis-bio-initiates-phase-1b-fortress-trial-of-ng-350a-for-locally-advanced-rectal-cancer 2025-04-03T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pbm-reform-and-340b-program-changes-lead-federal-healthcare-policy-agenda 2025-04-03T02:33:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pbm-reform-and-340b-program-changes-lead-federal-healthcare-policy-agenda 2025-04-03T02:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-s-edg-7500-shows-promise-in-phase-2-hcm-trial-with-improved-safety-profile 2025-04-03T02:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edgewise-s-edg-7500-shows-promise-in-phase-2-hcm-trial-with-improved-safety-profile 2025-04-03T02:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/lift-biosciences-advances-first-in-class-neutrophil-therapy-toward-clinical-trials-with-strategic-partnerships 2025-04-03T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lift-biosciences-advances-first-in-class-neutrophil-therapy-toward-clinical-trials-with-strategic-partnerships 2025-04-03T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-uncovers-significant-data-integrity-issues-at-indian-contract-research-organization 2025-04-03T01:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-uncovers-significant-data-integrity-issues-at-indian-contract-research-organization 2025-04-03T01:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/novel-dna-aptamers-deliver-dual-action-therapy-against-leukemia-stem-cells 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-dna-aptamers-deliver-dual-action-therapy-against-leukemia-stem-cells 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-affordability-crisis-deepens-35-of-americans-unable-to-access-quality-care 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-affordability-crisis-deepens-35-of-americans-unable-to-access-quality-care 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/endoziptm-automated-endoscopic-system-shows-11-4-weight-loss-and-improved-comorbidities-in-obesity-trial 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endoziptm-automated-endoscopic-system-shows-11-4-weight-loss-and-improved-comorbidities-in-obesity-trial 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-deletion-strategy-shows-promise-for-treating-short-bowel-syndrome 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-deletion-strategy-shows-promise-for-treating-short-bowel-syndrome 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-implements-bifurcated-patent-review-process-creating-new-hurdles-for-challengers 2025-04-02T23:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspto-implements-bifurcated-patent-review-process-creating-new-hurdles-for-challengers 2025-04-02T23:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-upholds-fda-approval-of-elanco-s-ammonia-reducing-cattle-drug-experior 2025-04-02T22:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-upholds-fda-approval-of-elanco-s-ammonia-reducing-cattle-drug-experior 2025-04-02T22:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-high-dose-ocrevus-fails-phase-3-trial-for-multiple-sclerosis-boosting-tg-therapeutics 2025-04-02T20:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-high-dose-ocrevus-fails-phase-3-trial-for-multiple-sclerosis-boosting-tg-therapeutics 2025-04-02T20:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/mesoblast-s-ryoncil-receives-us-fda-orphan-drug-approval-driving-15-share-price-surge 2025-04-02T20:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mesoblast-s-ryoncil-receives-us-fda-orphan-drug-approval-driving-15-share-price-surge 2025-04-02T20:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/patient-organizations-emerge-as-critical-partners-in-drug-development-and-clinical-research 2025-04-02T20:02:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-organizations-emerge-as-critical-partners-in-drug-development-and-clinical-research 2025-04-02T20:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-native-orthopaedics-dragonfly-technology-for-meniscal-root-repair 2025-04-02T19:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-native-orthopaedics-dragonfly-technology-for-meniscal-root-repair 2025-04-02T19:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-misses-deadline-for-full-approval-decision-on-novavax-s-covid-19-vaccine 2025-04-02T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-misses-deadline-for-full-approval-decision-on-novavax-s-covid-19-vaccine 2025-04-02T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-pioneering-zolar-trial-of-tlx300-cdx-for-advanced-soft-tissue-sarcoma 2025-04-02T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-pioneering-zolar-trial-of-tlx300-cdx-for-advanced-soft-tissue-sarcoma 2025-04-02T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-ocrevus-shows-strong-efficacy-in-musette-phase-iii-trial-for-multiple-sclerosis 2025-04-02T19:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-ocrevus-shows-strong-efficacy-in-musette-phase-iii-trial-for-multiple-sclerosis 2025-04-02T19:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-shows-greater-regulatory-flexibility-for-first-in-class-drugs-compared-to-ema-study-reveals 2025-04-02T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-shows-greater-regulatory-flexibility-for-first-in-class-drugs-compared-to-ema-study-reveals 2025-04-02T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-upholds-fda-s-authority-to-deny-flavored-vaping-products 2025-04-02T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-upholds-fda-s-authority-to-deny-flavored-vaping-products 2025-04-02T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/africa-launches-continental-medicine-approval-system-with-first-five-products 2025-04-02T19:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/africa-launches-continental-medicine-approval-system-with-first-five-products 2025-04-02T19:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-palynziq-shows-promising-results-in-adolescents-with-pku-setting-stage-for-label-expansion 2025-04-02T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-s-palynziq-shows-promising-results-in-adolescents-with-pku-setting-stage-for-label-expansion 2025-04-02T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/atsena-therapeutics-secures-150m-series-c-funding-to-advance-ocular-gene-therapies-for-inherited-blindness 2025-04-02T17:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atsena-therapeutics-secures-150m-series-c-funding-to-advance-ocular-gene-therapies-for-inherited-blindness 2025-04-02T17:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/vopemed-secures-2-29m-pre-seed-funding-to-advance-ai-powered-surgical-visualization-technology 2025-04-02T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vopemed-secures-2-29m-pre-seed-funding-to-advance-ai-powered-surgical-visualization-technology 2025-04-02T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-grants-orphan-designation-to-pharvaris-deucrictibant-for-bradykinin-mediated-angioedema 2025-04-02T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-grants-orphan-designation-to-pharvaris-deucrictibant-for-bradykinin-mediated-angioedema 2025-04-02T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-strengthens-intellectual-property-portfolio-with-new-patent-filings-for-ht-001-and-ht-kit 2025-04-02T16:42:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-strengthens-intellectual-property-portfolio-with-new-patent-filings-for-ht-001-and-ht-kit 2025-04-02T16:42:36+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-phase-iii-musette-trial-confirms-current-ocrevus-dose-optimal-for-multiple-sclerosis 2025-04-02T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-phase-iii-musette-trial-confirms-current-ocrevus-dose-optimal-for-multiple-sclerosis 2025-04-02T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/oncozenge-bolsters-phase-3-team-for-bupizengetm-as-company-prepares-for-pivotal-trial-in-oral-mucositis 2025-04-02T16:39:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncozenge-bolsters-phase-3-team-for-bupizengetm-as-company-prepares-for-pivotal-trial-in-oral-mucositis 2025-04-02T16:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/kyowa-kirin-and-la-jolla-institute-extend-35-year-research-alliance-with-focus-on-cell-and-gene-therapies 2025-04-02T16:39:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyowa-kirin-and-la-jolla-institute-extend-35-year-research-alliance-with-focus-on-cell-and-gene-therapies 2025-04-02T16:39:31+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-ht-alz-shows-promising-dual-action-against-alzheimer-s-in-preclinical-study 2025-04-02T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-ht-alz-shows-promising-dual-action-against-alzheimer-s-in-preclinical-study 2025-04-02T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/nulibry-shows-significant-survival-benefits-in-ultra-rare-mocd-type-a-landmark-clinical-evidence-published 2025-04-02T16:38:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nulibry-shows-significant-survival-benefits-in-ultra-rare-mocd-type-a-landmark-clinical-evidence-published 2025-04-02T16:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-s-mrna-therapy-shows-promise-in-liver-cancer-treatment 2025-04-02T16:38:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-s-mrna-therapy-shows-promise-in-liver-cancer-treatment 2025-04-02T16:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-launches-ai-powered-center-to-revolutionize-small-molecule-drug-discovery 2025-04-02T16:38:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-launches-ai-powered-center-to-revolutionize-small-molecule-drug-discovery 2025-04-02T16:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-studies-confirm-bevacizumab-biosimilars-deliver-cost-savings-and-equivalent-clinical-outcomes-in-metastatic-colorectal-cancer 2025-04-02T16:38:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-studies-confirm-bevacizumab-biosimilars-deliver-cost-savings-and-equivalent-clinical-outcomes-in-metastatic-colorectal-cancer 2025-04-02T16:38:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-revvity-s-automated-latent-tuberculosis-test-enhancing-diagnostic-efficiency 2025-04-02T16:37:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-revvity-s-automated-latent-tuberculosis-test-enhancing-diagnostic-efficiency 2025-04-02T16:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-launches-japan-s-first-over-the-counter-proton-pump-inhibitor-pariet-s 2025-04-02T15:38:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-launches-japan-s-first-over-the-counter-proton-pump-inhibitor-pariet-s 2025-04-02T15:38:04+00:00 hourly 0.9 https://trial.medpath.com/news/artis-biosolutions-launches-with-landmark-bio-acquisition-to-transform-advanced-therapy-manufacturing 2025-04-02T14:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artis-biosolutions-launches-with-landmark-bio-acquisition-to-transform-advanced-therapy-manufacturing 2025-04-02T14:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/withings-bpm-vision-blood-pressure-monitor-receives-fda-clearance-and-launches-in-us-market 2025-04-02T14:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/withings-bpm-vision-blood-pressure-monitor-receives-fda-clearance-and-launches-in-us-market 2025-04-02T14:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/helsinn-submits-new-akynzeo-r-formulation-to-ema-for-chemotherapy-induced-nausea-and-vomiting 2025-04-02T14:03:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helsinn-submits-new-akynzeo-r-formulation-to-ema-for-chemotherapy-induced-nausea-and-vomiting 2025-04-02T14:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/silmitasertib-shows-promise-in-advanced-basal-cell-carcinoma-patients-with-no-treatment-options 2025-04-02T13:37:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silmitasertib-shows-promise-in-advanced-basal-cell-carcinoma-patients-with-no-treatment-options 2025-04-02T13:37:08+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-s-parkinson-s-immunotherapy-shows-promising-results-in-phase-2-trial 2025-04-02T13:37:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ac-immune-s-parkinson-s-immunotherapy-shows-promising-results-in-phase-2-trial 2025-04-02T13:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/multiomic-health-and-alloy-therapeutics-partner-to-develop-precision-kidney-medicines-using-ai 2025-04-02T13:37:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiomic-health-and-alloy-therapeutics-partner-to-develop-precision-kidney-medicines-using-ai 2025-04-02T13:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-s-gugutams-launches-in-mexico-as-aditams-first-dual-opg-ed-combination-therapy-enters-latin-american-market 2025-04-02T13:36:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanmi-s-gugutams-launches-in-mexico-as-aditams-first-dual-opg-ed-combination-therapy-enters-latin-american-market 2025-04-02T13:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/jointmedica-launches-ide-study-for-novel-polymotion-r-hip-resurfacing-system 2025-04-02T13:36:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jointmedica-launches-ide-study-for-novel-polymotion-r-hip-resurfacing-system 2025-04-02T13:36:20+00:00 hourly 0.9 https://trial.medpath.com/news/asia-pacific-leads-global-surge-in-infectious-disease-clinical-trials-with-70-growth-rate 2025-04-02T13:36:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asia-pacific-leads-global-surge-in-infectious-disease-clinical-trials-with-70-growth-rate 2025-04-02T13:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/new-antibiotic-class-discovered-in-soil-sample-could-combat-drug-resistant-bacteria 2025-04-02T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-antibiotic-class-discovered-in-soil-sample-could-combat-drug-resistant-bacteria 2025-04-02T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/accord-healthcare-secures-positive-chmp-opinion-for-denosumab-biosimilars-targeting-osteoporosis-and-oncology 2025-04-02T10:36:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accord-healthcare-secures-positive-chmp-opinion-for-denosumab-biosimilars-targeting-osteoporosis-and-oncology 2025-04-02T10:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/first-vista-inhibitor-expected-to-receive-fda-approval-by-2028-according-to-new-research 2025-04-02T10:35:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-vista-inhibitor-expected-to-receive-fda-approval-by-2028-according-to-new-research 2025-04-02T10:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-wireless-catheter-free-urodynamics-system-for-bladder-dysfunction-testing 2025-04-02T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-wireless-catheter-free-urodynamics-system-for-bladder-dysfunction-testing 2025-04-02T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-prepares-for-multiple-new-product-launches-in-2025-following-strong-r-d-investment 2025-04-02T04:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-prepares-for-multiple-new-product-launches-in-2025-following-strong-r-d-investment 2025-04-02T04:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/jynneos-vaccine-shows-reduced-efficacy-against-mpox-in-hiv-patients-study-reveals 2025-04-02T04:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jynneos-vaccine-shows-reduced-efficacy-against-mpox-in-hiv-patients-study-reveals 2025-04-02T04:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/oculis-expands-privosegtor-development-to-naion-and-multiple-sclerosis-following-positive-phase-2-results 2025-04-02T03:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oculis-expands-privosegtor-development-to-naion-and-multiple-sclerosis-following-positive-phase-2-results 2025-04-02T03:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/scientific-industries-launches-dots-mps-for-cell-culture-biopharma-market-reports-24-bioprocessing-revenue-growth 2025-04-02T03:03:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientific-industries-launches-dots-mps-for-cell-culture-biopharma-market-reports-24-bioprocessing-revenue-growth 2025-04-02T03:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-promise-for-novel-intraperitoneal-therapy-in-peritoneal-metastases 2025-04-02T02:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-promise-for-novel-intraperitoneal-therapy-in-peritoneal-metastases 2025-04-02T02:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-overturns-fda-s-laboratory-developed-test-regulation-in-major-win-for-diagnostic-industry 2025-04-02T01:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-overturns-fda-s-laboratory-developed-test-regulation-in-major-win-for-diagnostic-industry 2025-04-02T01:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/japan-prioritizes-14-drug-loss-products-for-urgent-domestic-development-to-address-critical-medical-needs 2025-04-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-prioritizes-14-drug-loss-products-for-urgent-domestic-development-to-address-critical-medical-needs 2025-04-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jabez-biosciences-advances-novel-dhodh-inhibitor-jbz-001-in-phase-1-oncology-trial 2025-04-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jabez-biosciences-advances-novel-dhodh-inhibitor-jbz-001-in-phase-1-oncology-trial 2025-04-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-launches-groundbreaking-study-on-rapidly-progressive-alzheimer-s-disease 2025-04-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-launches-groundbreaking-study-on-rapidly-progressive-alzheimer-s-disease 2025-04-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-opts-in-for-global-license-of-abbisko-s-pimicotinib-for-85m 2025-04-01T22:35:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-opts-in-for-global-license-of-abbisko-s-pimicotinib-for-85m 2025-04-01T22:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/ynvisible-partners-with-ccl-design-to-scale-production-of-ultra-low-power-e-paper-displays 2025-04-01T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ynvisible-partners-with-ccl-design-to-scale-production-of-ultra-low-power-e-paper-displays 2025-04-01T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glucotrack-advances-to-clinical-stage-with-innovative-implantable-continuous-blood-glucose-monitor 2025-04-01T19:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glucotrack-advances-to-clinical-stage-with-innovative-implantable-continuous-blood-glucose-monitor 2025-04-01T19:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/nih-terminates-funding-for-vaccine-hesitancy-research-amid-rising-disease-outbreaks 2025-04-01T19:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-terminates-funding-for-vaccine-hesitancy-research-amid-rising-disease-outbreaks 2025-04-01T19:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/entvin-ai-secures-500k-from-y-combinator-to-transform-fda-drug-approval-process 2025-04-01T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entvin-ai-secures-500k-from-y-combinator-to-transform-fda-drug-approval-process 2025-04-01T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/cvac-system-demonstrates-superior-stone-clearance-in-multiple-real-world-studies-at-aua-2025 2025-04-01T18:00:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cvac-system-demonstrates-superior-stone-clearance-in-multiple-real-world-studies-at-aua-2025 2025-04-01T18:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/d-wave-and-japan-tobacco-pioneer-quantum-enhanced-ai-for-drug-discovery 2025-04-01T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/d-wave-and-japan-tobacco-pioneer-quantum-enhanced-ai-for-drug-discovery 2025-04-01T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/alzheon-s-valiltramiprosate-shows-promising-results-for-early-stage-alzheimer-s-in-apoe4-homozygotes 2025-04-01T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheon-s-valiltramiprosate-shows-promising-results-for-early-stage-alzheimer-s-in-apoe4-homozygotes 2025-04-01T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/ema-proposes-streamlined-approval-process-for-biosimilars-to-enhance-patient-access 2025-04-01T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-proposes-streamlined-approval-process-for-biosimilars-to-enhance-patient-access 2025-04-01T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-medical-technology-s-ilm-blue-receives-nmpa-approval-in-china-expanding-surgical-options-for-retinal-surgeons 2025-04-01T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeiss-medical-technology-s-ilm-blue-receives-nmpa-approval-in-china-expanding-surgical-options-for-retinal-surgeons 2025-04-01T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-yingli-pharma-s-phase-iii-trial-for-novel-ptcl-treatment-linperlisib 2025-04-01T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-yingli-pharma-s-phase-iii-trial-for-novel-ptcl-treatment-linperlisib 2025-04-01T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-freeze-dried-jynneos-vaccine-for-mpox-and-smallpox-prevention 2025-04-01T16:35:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-freeze-dried-jynneos-vaccine-for-mpox-and-smallpox-prevention 2025-04-01T16:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-launches-boruzu-first-ready-to-use-bortezomib-injection-for-multiple-myeloma-treatment 2025-04-01T16:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-launches-boruzu-first-ready-to-use-bortezomib-injection-for-multiple-myeloma-treatment 2025-04-01T16:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/selected-til-therapy-combined-with-pembrolizumab-shows-promising-results-for-metastatic-gastrointestinal-cancers 2025-04-01T16:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selected-til-therapy-combined-with-pembrolizumab-shows-promising-results-for-metastatic-gastrointestinal-cancers 2025-04-01T16:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/avalyn-s-inhaled-nintedanib-shows-promising-safety-profile-in-phase-1-trials-for-ipf-treatment 2025-04-01T16:34:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalyn-s-inhaled-nintedanib-shows-promising-safety-profile-in-phase-1-trials-for-ipf-treatment 2025-04-01T16:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/sernova-s-cell-pouch-bio-hybrid-organ-shows-promise-in-type-1-diabetes-clinical-trial 2025-04-01T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sernova-s-cell-pouch-bio-hybrid-organ-shows-promise-in-type-1-diabetes-clinical-trial 2025-04-01T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-sells-cantrixil-intellectual-property-rights-to-vivesto-for-1-million 2025-04-01T14:33:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-therapeutics-sells-cantrixil-intellectual-property-rights-to-vivesto-for-1-million 2025-04-01T14:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/vaxcyte-s-vax-24-shows-promising-results-despite-phase-2-serotype-misses-in-infant-study 2025-04-01T13:38:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxcyte-s-vax-24-shows-promising-results-despite-phase-2-serotype-misses-in-infant-study 2025-04-01T13:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/esteve-acquires-global-rights-to-increlex-for-rare-growth-disorder-treatment 2025-04-01T13:38:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esteve-acquires-global-rights-to-increlex-for-rare-growth-disorder-treatment 2025-04-01T13:38:32+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-reveals-promising-demographics-in-mindful-phase-ii-alzheimer-s-trial 2025-04-01T13:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-reveals-promising-demographics-in-mindful-phase-ii-alzheimer-s-trial 2025-04-01T13:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/cerevance-s-solengepras-fails-primary-endpoint-in-phase-ii-parkinson-s-trial-shows-promise-for-non-motor-symptoms 2025-04-01T13:36:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerevance-s-solengepras-fails-primary-endpoint-in-phase-ii-parkinson-s-trial-shows-promise-for-non-motor-symptoms 2025-04-01T13:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/navigo-proteins-and-sck-cen-partner-to-advance-terbium-161-based-radiotheranostics 2025-04-01T13:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigo-proteins-and-sck-cen-partner-to-advance-terbium-161-based-radiotheranostics 2025-04-01T13:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/akums-launches-first-in-india-ripasudil-timolol-combination-eye-drops-for-glaucoma-treatment 2025-04-01T13:36:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akums-launches-first-in-india-ripasudil-timolol-combination-eye-drops-for-glaucoma-treatment 2025-04-01T13:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/mepsgen-launches-nanocaliburtm-in-us-advanced-microfluidic-platform-for-scalable-nanoparticle-production 2025-04-01T13:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mepsgen-launches-nanocaliburtm-in-us-advanced-microfluidic-platform-for-scalable-nanoparticle-production 2025-04-01T13:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-advances-novel-pet-imaging-biomarker-for-multiple-sclerosis-with-first-patient-scan 2025-04-01T13:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-biopharma-advances-novel-pet-imaging-biomarker-for-multiple-sclerosis-with-first-patient-scan 2025-04-01T13:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/proofpilot-and-inspire-form-strategic-partnership-to-enhance-clinical-trial-recruitment 2025-04-01T13:35:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proofpilot-and-inspire-form-strategic-partnership-to-enhance-clinical-trial-recruitment 2025-04-01T13:35:47+00:00 hourly 0.9 https://trial.medpath.com/news/spanios-forms-strategic-partnerships-to-accelerate-cancer-drug-development-using-organoid-technology 2025-04-01T11:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spanios-forms-strategic-partnerships-to-accelerate-cancer-drug-development-using-organoid-technology 2025-04-01T11:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-showcases-promising-neurodegenerative-disease-research-at-ad-pd-2025 2025-04-01T07:35:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-showcases-promising-neurodegenerative-disease-research-at-ad-pd-2025 2025-04-01T07:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-pharmaceuticals-launches-generic-vancomycin-hydrochloride-injection-in-us-market 2025-04-01T07:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-pharmaceuticals-launches-generic-vancomycin-hydrochloride-injection-in-us-market 2025-04-01T07:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/zimmer-biomet-s-ribfix-advantage-system-receives-first-ce-mark-for-intrathoracic-rib-fixation 2025-04-01T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zimmer-biomet-s-ribfix-advantage-system-receives-first-ce-mark-for-intrathoracic-rib-fixation 2025-04-01T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/newron-pharmaceuticals-advances-pivotal-phase-iii-program-for-treatment-resistant-schizophrenia 2025-04-01T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newron-pharmaceuticals-advances-pivotal-phase-iii-program-for-treatment-resistant-schizophrenia 2025-04-01T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/psyence-biomed-accelerates-phase-iib-psilocybin-trial-for-adjustment-disorder-in-cancer-patients 2025-04-01T03:03:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psyence-biomed-accelerates-phase-iib-psilocybin-trial-for-adjustment-disorder-in-cancer-patients 2025-04-01T03:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/cell-and-gene-therapy-sector-overcomes-manufacturing-and-investment-hurdles-amid-30-funding-growth 2025-04-01T02:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-and-gene-therapy-sector-overcomes-manufacturing-and-investment-hurdles-amid-30-funding-growth 2025-04-01T02:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-trastuzumab-deruxtecan-efficacy-in-her2-positive-gastrointestinal-cancers 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-trastuzumab-deruxtecan-efficacy-in-her2-positive-gastrointestinal-cancers 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bd-launches-revolutionary-facsdiscover-a8-cell-analyzer-with-dual-breakthrough-technologies 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-launches-revolutionary-facsdiscover-a8-cell-analyzer-with-dual-breakthrough-technologies 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regulators-adapt-to-ai-revolution-in-healthcare-mhra-leads-with-new-guidance-and-sandbox-initiative 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulators-adapt-to-ai-revolution-in-healthcare-mhra-leads-with-new-guidance-and-sandbox-initiative 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-phase-iii-trials-testing-novel-immunotherapy-rilvegostomig-in-lung-and-breast-cancers 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-launches-phase-iii-trials-testing-novel-immunotherapy-rilvegostomig-in-lung-and-breast-cancers 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-significant-kidney-function-improvement-in-patients-with-obesity-and-heart-failure 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-shows-significant-kidney-function-improvement-in-patients-with-obesity-and-heart-failure 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dizal-to-present-novel-cancer-therapies-dzd8586-and-dzd6008-at-asco-2025 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dizal-to-present-novel-cancer-therapies-dzd8586-and-dzd6008-at-asco-2025 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/keros-therapeutics-reports-positive-phase-1-results-for-ker-065-in-duchenne-muscular-dystrophy-program 2025-03-31T22:38:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keros-therapeutics-reports-positive-phase-1-results-for-ker-065-in-duchenne-muscular-dystrophy-program 2025-03-31T22:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-cell-and-gene-therapy-champion-peter-marks-departs-leaving-industry-at-critical-juncture 2025-03-31T22:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-cell-and-gene-therapy-champion-peter-marks-departs-leaving-industry-at-critical-juncture 2025-03-31T22:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/rademikibart-shows-unprecedented-420ml-lung-function-improvement-in-phase-2-asthma-trial 2025-03-31T22:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rademikibart-shows-unprecedented-420ml-lung-function-improvement-in-phase-2-asthma-trial 2025-03-31T22:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/fortress-biotech-reports-strong-2024-results-with-two-fda-approvals-and-strategic-acquisition-deal 2025-03-31T22:35:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fortress-biotech-reports-strong-2024-results-with-two-fda-approvals-and-strategic-acquisition-deal 2025-03-31T22:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bavarian-nordic-s-freeze-dried-jynneos-vaccine-for-smallpox-and-mpox-prevention 2025-03-31T22:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bavarian-nordic-s-freeze-dried-jynneos-vaccine-for-smallpox-and-mpox-prevention 2025-03-31T22:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-submits-nda-for-novel-achondroplasia-treatment-with-multiple-clinical-benefits 2025-03-31T22:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-submits-nda-for-novel-achondroplasia-treatment-with-multiple-clinical-benefits 2025-03-31T22:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/chemotherapy-plus-local-excision-shows-promise-for-node-negative-low-rectal-cancer-patients 2025-03-31T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemotherapy-plus-local-excision-shows-promise-for-node-negative-low-rectal-cancer-patients 2025-03-31T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/abec-launches-advanced-therapy-bioreactor-to-transform-cell-therapy-manufacturing 2025-03-31T19:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abec-launches-advanced-therapy-bioreactor-to-transform-cell-therapy-manufacturing 2025-03-31T19:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/cosmos-trial-cocoa-extract-shows-no-significant-long-term-benefits-for-age-related-macular-degeneration 2025-03-31T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmos-trial-cocoa-extract-shows-no-significant-long-term-benefits-for-age-related-macular-degeneration 2025-03-31T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/mitsubishi-tanabe-pharma-america-to-present-breakthrough-neurodegenerative-disease-research-at-aan-2025 2025-03-31T16:39:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitsubishi-tanabe-pharma-america-to-present-breakthrough-neurodegenerative-disease-research-at-aan-2025 2025-03-31T16:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/genomoncology-and-chronetyx-laboratories-partner-to-accelerate-cancer-treatment-through-advanced-genomic-testing 2025-03-31T16:39:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomoncology-and-chronetyx-laboratories-partner-to-accelerate-cancer-treatment-through-advanced-genomic-testing 2025-03-31T16:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-study-surgery-may-be-unnecessary-for-early-stage-breast-cancer-patients 2025-03-31T16:38:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-study-surgery-may-be-unnecessary-for-early-stage-breast-cancer-patients 2025-03-31T16:38:57+00:00 hourly 0.9 https://trial.medpath.com/news/promising-pipeline-for-soft-tissue-sarcoma-treatment-expands-with-130-therapies-in-development 2025-03-31T16:38:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-pipeline-for-soft-tissue-sarcoma-treatment-expands-with-130-therapies-in-development 2025-03-31T16:38:38+00:00 hourly 0.9 https://trial.medpath.com/news/ema-confirms-mysimba-s-cardiovascular-safety-for-one-year-use-in-weight-management 2025-03-31T16:38:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-confirms-mysimba-s-cardiovascular-safety-for-one-year-use-in-weight-management 2025-03-31T16:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-luye-pharma-s-twice-weekly-rivastigmine-patch-for-alzheimer-s-disease 2025-03-31T16:37:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-luye-pharma-s-twice-weekly-rivastigmine-patch-for-alzheimer-s-disease 2025-03-31T16:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/positron-corporation-secures-8-million-investment-to-expand-pet-ct-imaging-technology 2025-03-31T15:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/positron-corporation-secures-8-million-investment-to-expand-pet-ct-imaging-technology 2025-03-31T15:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-ideaya-s-darovasertib-for-neoadjuvant-uveal-melanoma 2025-03-31T13:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-ideaya-s-darovasertib-for-neoadjuvant-uveal-melanoma 2025-03-31T13:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/isomorphic-labs-secures-600-million-to-advance-ai-powered-drug-discovery-platform 2025-03-31T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isomorphic-labs-secures-600-million-to-advance-ai-powered-drug-discovery-platform 2025-03-31T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-submits-nda-for-novel-antipsychotic-bysanti-to-treat-bipolar-i-disorder-and-schizophrenia 2025-03-31T13:33:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-submits-nda-for-novel-antipsychotic-bysanti-to-treat-bipolar-i-disorder-and-schizophrenia 2025-03-31T13:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-expedited-pathway-for-tharimmune-s-th104-opioid-defense-drug-without-additional-clinical-trials 2025-03-31T13:33:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-expedited-pathway-for-tharimmune-s-th104-opioid-defense-drug-without-additional-clinical-trials 2025-03-31T13:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-expands-proceed-trial-to-include-intravenous-administration-of-novel-anti-pacap-antibody-for-migraine-prevention 2025-03-31T13:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-expands-proceed-trial-to-include-intravenous-administration-of-novel-anti-pacap-antibody-for-migraine-prevention 2025-03-31T13:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/hybrid-closed-loop-systems-show-significant-glycemic-benefits-for-pregnant-women-with-type-1-diabetes 2025-03-31T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hybrid-closed-loop-systems-show-significant-glycemic-benefits-for-pregnant-women-with-type-1-diabetes 2025-03-31T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-triclip-shows-sustained-benefits-for-tricuspid-regurgitation-patients-in-two-year-study 2025-03-31T13:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-s-triclip-shows-sustained-benefits-for-tricuspid-regurgitation-patients-in-two-year-study 2025-03-31T13:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/eagle-pharmaceuticals-secures-69-million-deal-to-monetize-bendeka-royalties 2025-03-31T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eagle-pharmaceuticals-secures-69-million-deal-to-monetize-bendeka-royalties 2025-03-31T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-s-maat034-shows-promise-in-enhancing-immunotherapy-response-for-cancer-treatment 2025-03-31T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-s-maat034-shows-promise-in-enhancing-immunotherapy-response-for-cancer-treatment 2025-03-31T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-leadership-shakeup-peter-marks-forced-resignation-sends-shockwaves-through-biopharma-industry 2025-03-31T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-leadership-shakeup-peter-marks-forced-resignation-sends-shockwaves-through-biopharma-industry 2025-03-31T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/cadrenal-therapeutics-advances-towards-phase-3-trial-of-tecarfarin-for-lvad-patients 2025-03-31T10:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadrenal-therapeutics-advances-towards-phase-3-trial-of-tecarfarin-for-lvad-patients 2025-03-31T10:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/geopolitical-shifts-and-industry-expansion-navigating-the-future-of-cell-and-gene-therapy-in-2025 2025-03-31T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geopolitical-shifts-and-industry-expansion-navigating-the-future-of-cell-and-gene-therapy-in-2025 2025-03-31T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/marker-therapeutics-mt-601-shows-78-response-rate-in-refractory-lymphoma-patients 2025-03-31T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marker-therapeutics-mt-601-shows-78-response-rate-in-refractory-lymphoma-patients 2025-03-31T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotest-reports-6-sales-growth-in-2024-fda-approves-yimmugo-for-us-market 2025-03-31T07:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotest-reports-6-sales-growth-in-2024-fda-approves-yimmugo-for-us-market 2025-03-31T07:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharmaceuticals-the-next-frontier-in-precision-oncology-as-big-pharma-competes-for-market-share 2025-03-31T07:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharmaceuticals-the-next-frontier-in-precision-oncology-as-big-pharma-competes-for-market-share 2025-03-31T07:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/nmpa-approves-gyre-therapeutics-clinical-trial-for-pirfenidone-in-oncology-related-lung-complications 2025-03-31T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nmpa-approves-gyre-therapeutics-clinical-trial-for-pirfenidone-in-oncology-related-lung-complications 2025-03-31T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/has-healthcare-advanced-synthesis-sa-acquires-cerbios-pharma-sa-to-create-leading-international-group-in-the-cdmo-sector-backed-by-65-equity-partners 2025-03-31T06:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/has-healthcare-advanced-synthesis-sa-acquires-cerbios-pharma-sa-to-create-leading-international-group-in-the-cdmo-sector-backed-by-65-equity-partners 2025-03-31T06:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/nls-pharmaceutics-secures-28-million-in-financing-to-advance-merger-with-kadimastem-and-cell-therapy-pipeline 2025-03-31T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nls-pharmaceutics-secures-28-million-in-financing-to-advance-merger-with-kadimastem-and-cell-therapy-pipeline 2025-03-31T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/novotech-secures-major-investment-from-gic-temasek-and-tpg-to-expand-global-cro-operations 2025-03-31T05:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novotech-secures-major-investment-from-gic-temasek-and-tpg-to-expand-global-cro-operations 2025-03-31T05:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bcma-directed-car-t-cell-therapy-shows-promising-efficacy-in-relapsed-refractory-multiple-myeloma-and-al-amyloidosis 2025-03-31T02:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bcma-directed-car-t-cell-therapy-shows-promising-efficacy-in-relapsed-refractory-multiple-myeloma-and-al-amyloidosis 2025-03-31T02:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-submits-bla-for-sibeprenlimab-a-novel-targeted-therapy-for-iga-nephropathy 2025-03-31T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-submits-bla-for-sibeprenlimab-a-novel-targeted-therapy-for-iga-nephropathy 2025-03-31T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/trethera-reports-disease-stabilization-in-late-stage-als-patient-treated-with-tre-515 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trethera-reports-disease-stabilization-in-late-stage-als-patient-treated-with-tre-515 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-secures-critical-chinese-patent-for-bv100-advancing-treatment-for-deadly-antibiotic-resistant-infections 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-secures-critical-chinese-patent-for-bv100-advancing-treatment-for-deadly-antibiotic-resistant-infections 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/reach3-trial-update-ruxolitinib-shows-promising-efficacy-in-steroid-refractory-chronic-gvhd 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reach3-trial-update-ruxolitinib-shows-promising-efficacy-in-steroid-refractory-chronic-gvhd 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-advances-from-laboratory-to-clinic-with-250-active-trials-across-multiple-therapeutic-areas 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-advances-from-laboratory-to-clinic-with-250-active-trials-across-multiple-therapeutic-areas 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bhf-protect-tavi-trial-fails-to-show-benefit-of-cerebral-embolic-protection-during-tavi 2025-03-30T22:32:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bhf-protect-tavi-trial-fails-to-show-benefit-of-cerebral-embolic-protection-during-tavi 2025-03-30T22:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/reviva-to-present-long-term-phase-3-data-for-brilaroxazine-in-schizophrenia-at-sirs-congress 2025-03-30T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reviva-to-present-long-term-phase-3-data-for-brilaroxazine-in-schizophrenia-at-sirs-congress 2025-03-30T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/score-study-semaglutide-2-4-mg-shows-57-reduction-in-cardiovascular-events-in-real-world-analysis 2025-03-30T17:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/score-study-semaglutide-2-4-mg-shows-57-reduction-in-cardiovascular-events-in-real-world-analysis 2025-03-30T17:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/fresh-up-trial-challenges-fluid-restriction-guidelines-in-chronic-heart-failure-patients 2025-03-30T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresh-up-trial-challenges-fluid-restriction-guidelines-in-chronic-heart-failure-patients 2025-03-30T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-evolut-tavr-system-demonstrates-superior-durability-and-performance-at-five-year-mark 2025-03-30T16:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-evolut-tavr-system-demonstrates-superior-durability-and-performance-at-five-year-mark 2025-03-30T16:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/brii-bio-s-brii-179-shows-promise-in-identifying-responders-for-hbv-functional-cure 2025-03-30T13:32:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brii-bio-s-brii-179-shows-promise-in-identifying-responders-for-hbv-functional-cure 2025-03-30T13:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/ninerafaxstat-shows-promise-in-phase-2-trial-for-cardiometabolic-hfpef-patients 2025-03-30T13:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ninerafaxstat-shows-promise-in-phase-2-trial-for-cardiometabolic-hfpef-patients 2025-03-30T13:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/4f-pcc-demonstrates-superior-efficacy-over-frozen-plasma-in-managing-cardiac-surgery-bleeding 2025-03-30T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4f-pcc-demonstrates-superior-efficacy-over-frozen-plasma-in-managing-cardiac-surgery-bleeding 2025-03-30T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-chemotherapy-causes-greater-long-term-physical-health-decline-in-breast-cancer-survivors-than-endocrine-therapy 2025-03-30T13:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-chemotherapy-causes-greater-long-term-physical-health-decline-in-breast-cancer-survivors-than-endocrine-therapy 2025-03-30T13:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/kitea-health-secures-fda-fast-track-status-and-completes-groundbreaking-pediatric-brain-implant 2025-03-30T07:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kitea-health-secures-fda-fast-track-status-and-completes-groundbreaking-pediatric-brain-implant 2025-03-30T07:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/fremanezumab-demonstrates-long-term-efficacy-in-migraine-prevention-across-multiple-real-world-studies 2025-03-30T01:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fremanezumab-demonstrates-long-term-efficacy-in-migraine-prevention-across-multiple-real-world-studies 2025-03-30T01:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-launches-landmark-study-to-investigate-shingles-vaccine-s-potential-to-reduce-dementia-risk 2025-03-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-launches-landmark-study-to-investigate-shingles-vaccine-s-potential-to-reduce-dementia-risk 2025-03-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-lepodisiran-shows-95-reduction-in-lipoprotein-a-offering-new-hope-for-south-asian-heart-patients 2025-03-29T22:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-lepodisiran-shows-95-reduction-in-lipoprotein-a-offering-new-hope-for-south-asian-heart-patients 2025-03-29T22:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/rakovina-therapeutics-advances-novel-ai-discovered-parp1-and-atr-inhibitors-for-hard-to-treat-cancers 2025-03-29T22:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakovina-therapeutics-advances-novel-ai-discovered-parp1-and-atr-inhibitors-for-hard-to-treat-cancers 2025-03-29T22:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-apixaban-proves-effective-and-safer-for-extended-cancer-related-vte-prevention 2025-03-29T20:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-apixaban-proves-effective-and-safer-for-extended-cancer-related-vte-prevention 2025-03-29T20:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/bentracimab-shows-promising-results-in-phase-3-trial-for-reversing-ticagrelor-s-antiplatelet-effects 2025-03-29T19:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bentracimab-shows-promising-results-in-phase-3-trial-for-reversing-ticagrelor-s-antiplatelet-effects 2025-03-29T19:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/first-clinical-trial-shows-ai-therapy-bot-effective-for-depression-and-anxiety 2025-03-29T19:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-clinical-trial-shows-ai-therapy-bot-effective-for-depression-and-anxiety 2025-03-29T19:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-lorundrostat-shows-significant-promise-for-uncontrolled-hypertension-in-phase-2b-trial 2025-03-29T19:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-drug-lorundrostat-shows-significant-promise-for-uncontrolled-hypertension-in-phase-2b-trial 2025-03-29T19:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-s-vx-880-cell-therapy-enables-type-1-diabetes-patients-to-achieve-insulin-independence 2025-03-29T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-s-vx-880-cell-therapy-enables-type-1-diabetes-patients-to-achieve-insulin-independence 2025-03-29T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/immune-checkpoint-inhibitors-emerge-as-standard-of-care-for-early-stage-nsclc-new-data-shows 2025-03-29T16:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-checkpoint-inhibitors-emerge-as-standard-of-care-for-early-stage-nsclc-new-data-shows 2025-03-29T16:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/ozempic-significantly-improves-walking-distance-in-patients-with-type-2-diabetes-and-peripheral-artery-disease 2025-03-29T16:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ozempic-significantly-improves-walking-distance-in-patients-with-type-2-diabetes-and-peripheral-artery-disease 2025-03-29T16:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-advances-treg-exosome-platform-for-neurodegenerative-disease-treatment 2025-03-29T16:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-advances-treg-exosome-platform-for-neurodegenerative-disease-treatment 2025-03-29T16:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/cystic-fibrosis-foundation-invests-2-3-million-in-owlstone-medical-to-develop-breath-based-pathogen-test 2025-03-29T16:33:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cystic-fibrosis-foundation-invests-2-3-million-in-owlstone-medical-to-develop-breath-based-pathogen-test 2025-03-29T16:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-april-decisions-to-shape-future-of-key-therapies-dupixent-opdivo-and-nipocalimab-in-focus 2025-03-29T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-april-decisions-to-shape-future-of-key-therapies-dupixent-opdivo-and-nipocalimab-in-focus 2025-03-29T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/penetrium-shows-promising-anti-metastatic-effects-in-triple-negative-breast-cancer-preclinical-study 2025-03-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penetrium-shows-promising-anti-metastatic-effects-in-triple-negative-breast-cancer-preclinical-study 2025-03-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/esa-treatment-shows-survival-benefit-in-lower-risk-myelodysplastic-syndromes 2025-03-29T10:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esa-treatment-shows-survival-benefit-in-lower-risk-myelodysplastic-syndromes 2025-03-29T10:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-announces-major-restructuring-with-10000-job-cuts-raising-concerns-for-healthcare-regulation-and-drug-programs 2025-03-29T07:34:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-announces-major-restructuring-with-10000-job-cuts-raising-concerns-for-healthcare-regulation-and-drug-programs 2025-03-29T07:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/orca-bio-s-phase-iii-precision-t-study-shows-promise-for-novel-t-cell-immunotherapy-in-blood-cancers 2025-03-29T07:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orca-bio-s-phase-iii-precision-t-study-shows-promise-for-novel-t-cell-immunotherapy-in-blood-cancers 2025-03-29T07:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/telehealth-evolution-patient-satisfaction-reaches-record-highs-as-virtual-primary-care-transforms-healthcare-access 2025-03-29T02:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telehealth-evolution-patient-satisfaction-reaches-record-highs-as-virtual-primary-care-transforms-healthcare-access 2025-03-29T02:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/pmi-expands-iqos-heated-tobacco-system-to-fort-lauderdale-following-successful-austin-launch 2025-03-29T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmi-expands-iqos-heated-tobacco-system-to-fort-lauderdale-following-successful-austin-launch 2025-03-29T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-roche-s-polivy-as-first-new-frontline-dlbcl-treatment-in-nearly-20-years 2025-03-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-roche-s-polivy-as-first-new-frontline-dlbcl-treatment-in-nearly-20-years 2025-03-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/solaxa-advances-slx-100-to-phase-3-trial-for-rare-spinocerebellar-ataxia-type-27b 2025-03-28T22:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solaxa-advances-slx-100-to-phase-3-trial-for-rare-spinocerebellar-ataxia-type-27b 2025-03-28T22:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/uplizna-shows-remarkable-efficacy-in-reducing-flares-and-glucocorticoid-dependence-in-igg4-related-disease 2025-03-28T22:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uplizna-shows-remarkable-efficacy-in-reducing-flares-and-glucocorticoid-dependence-in-igg4-related-disease 2025-03-28T22:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-halts-vx-264-diabetes-treatment-after-phase-1-2-trial-fails-to-meet-efficacy-endpoint 2025-03-28T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-halts-vx-264-diabetes-treatment-after-phase-1-2-trial-fails-to-meet-efficacy-endpoint 2025-03-28T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/prothena-faces-phase-3-trial-setback-in-neurodegenerative-disease-program 2025-03-28T20:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prothena-faces-phase-3-trial-setback-in-neurodegenerative-disease-program 2025-03-28T20:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-averoa-s-xoanacyl-for-chronic-kidney-disease-treatment 2025-03-28T19:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-approval-of-averoa-s-xoanacyl-for-chronic-kidney-disease-treatment 2025-03-28T19:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/labtician-ophthalmics-launches-lab-triactiv-a-novel-triple-action-artificial-tear-for-dry-eye-relief 2025-03-28T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labtician-ophthalmics-launches-lab-triactiv-a-novel-triple-action-artificial-tear-for-dry-eye-relief 2025-03-28T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-pluvicto-approval-for-earlier-treatment-of-metastatic-prostate-cancer 2025-03-28T19:34:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-pluvicto-approval-for-earlier-treatment-of-metastatic-prostate-cancer 2025-03-28T19:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-s-oral-mc1r-agonist-shows-promising-results-in-phase-2-ulcerative-colitis-trial 2025-03-28T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palatin-s-oral-mc1r-agonist-shows-promising-results-in-phase-2-ulcerative-colitis-trial 2025-03-28T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-to-list-on-nasdaq-global-market-with-novel-blood-brain-barrier-therapeutics 2025-03-28T16:39:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-to-list-on-nasdaq-global-market-with-novel-blood-brain-barrier-therapeutics 2025-03-28T16:39:45+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-s-bnt327-shows-promising-85-response-rate-in-first-line-treatment-for-extensive-stage-sclc 2025-03-28T16:38:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-s-bnt327-shows-promising-85-response-rate-in-first-line-treatment-for-extensive-stage-sclc 2025-03-28T16:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/fulzerasib-cetuximab-combination-shows-promise-as-first-line-treatment-for-kras-g12c-mutated-nsclc 2025-03-28T16:37:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fulzerasib-cetuximab-combination-shows-promise-as-first-line-treatment-for-kras-g12c-mutated-nsclc 2025-03-28T16:37:40+00:00 hourly 0.9 https://trial.medpath.com/news/triple-combination-acne-gel-shows-efficacy-and-safety-in-hispanic-patients-and-long-term-use 2025-03-28T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-combination-acne-gel-shows-efficacy-and-safety-in-hispanic-patients-and-long-term-use 2025-03-28T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-withdraws-translarna-s-marketing-authorization-for-duchenne-muscular-dystrophy 2025-03-28T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-withdraws-translarna-s-marketing-authorization-for-duchenne-muscular-dystrophy 2025-03-28T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-first-at-home-test-for-three-common-stis-expanding-access-to-sexual-health-diagnostics 2025-03-28T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-first-at-home-test-for-three-common-stis-expanding-access-to-sexual-health-diagnostics 2025-03-28T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-milestone-s-cardamyst-for-psvt-citing-manufacturing-issues 2025-03-28T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-milestone-s-cardamyst-for-psvt-citing-manufacturing-issues 2025-03-28T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/cd46-targeting-adc-fg-3246-shows-promising-results-in-advanced-prostate-cancer-trial 2025-03-28T16:36:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd46-targeting-adc-fg-3246-shows-promising-results-in-advanced-prostate-cancer-trial 2025-03-28T16:36:41+00:00 hourly 0.9 https://trial.medpath.com/news/traws-pharma-announces-leadership-transition-as-ceo-werner-cautreels-retires 2025-03-28T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traws-pharma-announces-leadership-transition-as-ceo-werner-cautreels-retires 2025-03-28T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-reject-eli-lilly-s-alzheimer-s-drug-kisunla-over-safety-concerns 2025-03-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-reject-eli-lilly-s-alzheimer-s-drug-kisunla-over-safety-concerns 2025-03-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulatory-committee-rejects-eli-lilly-s-alzheimer-s-drug-kisunla-over-safety-concerns 2025-03-28T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulatory-committee-rejects-eli-lilly-s-alzheimer-s-drug-kisunla-over-safety-concerns 2025-03-28T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-s-telitacicept-shows-remarkable-98-response-rate-in-phase-3-trial-for-generalized-myasthenia-gravis 2025-03-28T10:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remegen-s-telitacicept-shows-remarkable-98-response-rate-in-phase-3-trial-for-generalized-myasthenia-gravis 2025-03-28T10:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/gedeon-richter-submits-tocilizumab-biosimilar-application-to-ema-for-multiple-indications 2025-03-28T10:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gedeon-richter-submits-tocilizumab-biosimilar-application-to-ema-for-multiple-indications 2025-03-28T10:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-vasorum-s-celt-acd-plus-vascular-closure-device-with-blood-signal-technology 2025-03-28T10:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-vasorum-s-celt-acd-plus-vascular-closure-device-with-blood-signal-technology 2025-03-28T10:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/first-human-transplant-of-sperm-producing-stem-cells-offers-hope-for-childhood-cancer-survivors 2025-03-28T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-human-transplant-of-sperm-producing-stem-cells-offers-hope-for-childhood-cancer-survivors 2025-03-28T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncozenge-and-molteni-farmaceutici-partner-for-bupizenge-commercialization-in-europe 2025-03-28T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncozenge-and-molteni-farmaceutici-partner-for-bupizenge-commercialization-in-europe 2025-03-28T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-pharmaceuticals-initiates-phase-1-trial-of-peripherally-restricted-cb1-inverse-agonist-for-obesity 2025-03-28T07:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corbus-pharmaceuticals-initiates-phase-1-trial-of-peripherally-restricted-cb1-inverse-agonist-for-obesity 2025-03-28T07:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/merlin-cp-gep-test-shows-breakthrough-results-in-melanoma-risk-assessment-and-treatment-planning 2025-03-28T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merlin-cp-gep-test-shows-breakthrough-results-in-melanoma-risk-assessment-and-treatment-planning 2025-03-28T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-medicine-launches-landmark-study-using-apple-watch-to-revolutionize-afib-treatment 2025-03-28T04:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-medicine-launches-landmark-study-using-apple-watch-to-revolutionize-afib-treatment 2025-03-28T04:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/biorestorative-therapies-reports-strong-financial-growth-and-clinical-advancements-in-2024 2025-03-28T02:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biorestorative-therapies-reports-strong-financial-growth-and-clinical-advancements-in-2024 2025-03-28T02:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-advances-bioengineered-vessel-technology-following-fda-approval-for-vascular-trauma 2025-03-28T02:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-advances-bioengineered-vessel-technology-following-fda-approval-for-vascular-trauma 2025-03-28T02:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/evolving-paradigm-addressing-women-s-underrepresentation-in-clinical-trials 2025-03-28T02:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolving-paradigm-addressing-women-s-underrepresentation-in-clinical-trials 2025-03-28T02:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/actinium-pharmaceuticals-unveils-atnm-400-a-breakthrough-non-psma-targeted-radiotherapy-for-prostate-cancer 2025-03-28T02:02:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actinium-pharmaceuticals-unveils-atnm-400-a-breakthrough-non-psma-targeted-radiotherapy-for-prostate-cancer 2025-03-28T02:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/port-7-shows-over-90-tumor-reduction-in-mesothelioma-preclinical-studies-first-in-human-trial-planned 2025-03-28T01:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/port-7-shows-over-90-tumor-reduction-in-mesothelioma-preclinical-studies-first-in-human-trial-planned 2025-03-28T01:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/curium-expands-european-nuclear-medicine-footprint-with-strategic-acquisitions-of-nucleis-and-monrol 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curium-expands-european-nuclear-medicine-footprint-with-strategic-acquisitions-of-nucleis-and-monrol 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-show-promise-as-novel-immunomodulatory-therapy-for-autoimmune-diseases 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt2-inhibitors-show-promise-as-novel-immunomodulatory-therapy-for-autoimmune-diseases 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medication-nonadherence-drives-125-billion-in-avoidable-healthcare-costs-and-200000-deaths-annually-in-europe 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medication-nonadherence-drives-125-billion-in-avoidable-healthcare-costs-and-200000-deaths-annually-in-europe 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/shanton-s-sap-001-shows-breakthrough-results-in-refractory-gout-phase-2b-trial 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shanton-s-sap-001-shows-breakthrough-results-in-refractory-gout-phase-2b-trial 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-reports-promising-results-for-vista-targeting-antibody-in-pd-l1-resistant-tumors 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensei-biotherapeutics-reports-promising-results-for-vista-targeting-antibody-in-pd-l1-resistant-tumors 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurogene-halts-high-dose-arm-of-rett-syndrome-gene-therapy-trial-following-serious-adverse-event 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurogene-halts-high-dose-arm-of-rett-syndrome-gene-therapy-trial-following-serious-adverse-event 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nirogacestat-shows-deepening-long-term-responses-in-desmoid-tumor-patients 2025-03-27T22:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nirogacestat-shows-deepening-long-term-responses-in-desmoid-tumor-patients 2025-03-27T22:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/cleerly-to-present-groundbreaking-ai-study-on-cardiovascular-risk-in-women-at-acc-25 2025-03-27T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleerly-to-present-groundbreaking-ai-study-on-cardiovascular-risk-in-women-at-acc-25 2025-03-27T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-reports-strong-clinical-results-and-ai-platform-advancements-in-2024-year-end-update 2025-03-27T22:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-reports-strong-clinical-results-and-ai-platform-advancements-in-2024-year-end-update 2025-03-27T22:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-expands-hyqvia-authorization-for-cidp-maintenance-therapy 2025-03-27T19:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-expands-hyqvia-authorization-for-cidp-maintenance-therapy 2025-03-27T19:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/urteste-to-launch-european-clinical-trials-for-novel-pancreatic-cancer-urine-test-in-q3-2025 2025-03-27T19:33:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urteste-to-launch-european-clinical-trials-for-novel-pancreatic-cancer-urine-test-in-q3-2025 2025-03-27T19:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/remote-patient-monitoring-revolution-how-covid-19-transformed-healthcare-delivery 2025-03-27T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remote-patient-monitoring-revolution-how-covid-19-transformed-healthcare-delivery 2025-03-27T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/spyglass-pharma-appoints-veteran-pharmaceutical-executive-as-chief-r-d-officer-to-advance-intraocular-drug-delivery-platform 2025-03-27T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spyglass-pharma-appoints-veteran-pharmaceutical-executive-as-chief-r-d-officer-to-advance-intraocular-drug-delivery-platform 2025-03-27T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/sirna-therapeutics-surge-over-150-industry-sponsored-clinical-trials-conducted-in-recent-years 2025-03-27T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirna-therapeutics-surge-over-150-industry-sponsored-clinical-trials-conducted-in-recent-years 2025-03-27T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/novel-immunotherapy-ost-her2-shows-promise-for-osteosarcoma-treatment-featured-in-pbs-documentary 2025-03-27T16:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-immunotherapy-ost-her2-shows-promise-for-osteosarcoma-treatment-featured-in-pbs-documentary 2025-03-27T16:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/scinai-to-acquire-pincell-advancing-novel-antibody-treatment-for-severe-skin-disorders 2025-03-27T16:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scinai-to-acquire-pincell-advancing-novel-antibody-treatment-for-severe-skin-disorders 2025-03-27T16:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-subcutaneous-pembrolizumab-shows-comparable-efficacy-to-iv-keytruda-with-significantly-reduced-administration-time 2025-03-27T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-subcutaneous-pembrolizumab-shows-comparable-efficacy-to-iv-keytruda-with-significantly-reduced-administration-time 2025-03-27T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/china-proposes-up-to-6-years-of-clinical-trial-data-exclusivity-in-draft-measures 2025-03-27T16:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-proposes-up-to-6-years-of-clinical-trial-data-exclusivity-in-draft-measures 2025-03-27T16:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-trial-designs-emerge-after-immunotherapy-setbacks-in-head-and-neck-cancer 2025-03-27T16:33:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-trial-designs-emerge-after-immunotherapy-setbacks-in-head-and-neck-cancer 2025-03-27T16:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/lupus-foundation-of-america-launches-lfa-lift-to-streamline-clinical-trials-and-accelerate-treatment-development 2025-03-27T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupus-foundation-of-america-launches-lfa-lift-to-streamline-clinical-trials-and-accelerate-treatment-development 2025-03-27T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/curevac-wins-key-patent-validity-decision-in-ongoing-mrna-litigation-against-biontech 2025-03-27T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curevac-wins-key-patent-validity-decision-in-ongoing-mrna-litigation-against-biontech 2025-03-27T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/spyre-therapeutics-initiates-phase-1-trial-of-novel-long-acting-il-23-antibody-for-ibd-treatment 2025-03-27T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spyre-therapeutics-initiates-phase-1-trial-of-novel-long-acting-il-23-antibody-for-ibd-treatment 2025-03-27T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/aeon-biopharma-appoints-rob-bancroft-as-new-ceo-to-lead-abp-450-therapeutic-development 2025-03-27T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aeon-biopharma-appoints-rob-bancroft-as-new-ceo-to-lead-abp-450-therapeutic-development 2025-03-27T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/ekf-diagnostics-appoints-gavin-jones-as-ceo-to-drive-point-of-care-growth-strategy 2025-03-27T15:35:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ekf-diagnostics-appoints-gavin-jones-as-ceo-to-drive-point-of-care-growth-strategy 2025-03-27T15:35:53+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-recalls-envista-intraocular-lenses-due-to-inflammatory-complications 2025-03-27T15:02:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-recalls-envista-intraocular-lenses-due-to-inflammatory-complications 2025-03-27T15:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/invivoscribe-s-leukostrat-cdx-flt3-mutation-assay-receives-regulatory-approval-in-uk-and-switzerland 2025-03-27T14:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivoscribe-s-leukostrat-cdx-flt3-mutation-assay-receives-regulatory-approval-in-uk-and-switzerland 2025-03-27T14:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-promising-survival-benefits-in-lung-cancer-and-strategic-advances-in-protein-degradation 2025-03-27T13:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyondspring-s-plinabulin-shows-promising-survival-benefits-in-lung-cancer-and-strategic-advances-in-protein-degradation 2025-03-27T13:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/yoda-therapeutics-initiates-phase-2-trial-of-ya-101-for-multiple-system-atrophy 2025-03-27T13:34:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yoda-therapeutics-initiates-phase-2-trial-of-ya-101-for-multiple-system-atrophy 2025-03-27T13:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/galatea-bio-secures-25m-to-build-global-biobank-focused-on-diverse-genetic-data 2025-03-27T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galatea-bio-secures-25m-to-build-global-biobank-focused-on-diverse-genetic-data 2025-03-27T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-s-xolair-biosimilar-avt23-achieves-positive-phase-iii-results-and-uk-regulatory-acceptance 2025-03-27T13:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-s-xolair-biosimilar-avt23-achieves-positive-phase-iii-results-and-uk-regulatory-acceptance 2025-03-27T13:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/drone-technology-trials-begin-for-rapid-delivery-of-radioactive-medicines-in-coventry 2025-03-27T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drone-technology-trials-begin-for-rapid-delivery-of-radioactive-medicines-in-coventry 2025-03-27T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-partners-with-cbcc-global-research-to-accelerate-brain-cancer-clinical-trials-in-india 2025-03-27T13:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-partners-with-cbcc-global-research-to-accelerate-brain-cancer-clinical-trials-in-india 2025-03-27T13:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/cnd-life-sciences-to-present-breakthrough-skin-biopsy-data-for-dementia-diagnosis-at-aan-2025 2025-03-27T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cnd-life-sciences-to-present-breakthrough-skin-biopsy-data-for-dementia-diagnosis-at-aan-2025 2025-03-27T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/alzinova-s-alz-101-vaccine-advances-to-phase-2-trial-following-successful-drug-substance-production 2025-03-27T09:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzinova-s-alz-101-vaccine-advances-to-phase-2-trial-following-successful-drug-substance-production 2025-03-27T09:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-precision-study-launches-3-fraction-sbrt-protocol-for-prostate-cancer-treatment 2025-03-27T09:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-precision-study-launches-3-fraction-sbrt-protocol-for-prostate-cancer-treatment 2025-03-27T09:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/intelligent-bio-solutions-expands-global-reach-with-strategic-partnership-in-spain-and-andorra 2025-03-27T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intelligent-bio-solutions-expands-global-reach-with-strategic-partnership-in-spain-and-andorra 2025-03-27T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-authorizes-4moving-biotech-s-phase-2a-trial-for-novel-knee-osteoarthritis-treatment 2025-03-27T08:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-authorizes-4moving-biotech-s-phase-2a-trial-for-novel-knee-osteoarthritis-treatment 2025-03-27T08:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-s-crofelemer-shows-promising-results-for-breast-cancer-patients-with-treatment-related-diarrhea 2025-03-27T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaguar-health-s-crofelemer-shows-promising-results-for-breast-cancer-patients-with-treatment-related-diarrhea 2025-03-27T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/polyrizon-advances-pl-14-allergy-blocker-with-successful-safety-study-and-clinical-strategy 2025-03-27T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyrizon-advances-pl-14-allergy-blocker-with-successful-safety-study-and-clinical-strategy 2025-03-27T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/glyconex-to-present-novel-glycan-targeting-adc-data-for-gastric-cancer-at-aacr-2025 2025-03-27T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glyconex-to-present-novel-glycan-targeting-adc-data-for-gastric-cancer-at-aacr-2025 2025-03-27T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tablet-formulation-of-livmarli-for-rare-pediatric-liver-diseases 2025-03-27T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tablet-formulation-of-livmarli-for-rare-pediatric-liver-diseases 2025-03-27T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/tecentriq-and-avastin-combination-now-funded-for-advanced-liver-cancer-in-new-zealand 2025-03-27T05:02:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tecentriq-and-avastin-combination-now-funded-for-advanced-liver-cancer-in-new-zealand 2025-03-27T05:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/northstrive-biosciences-expands-licensing-agreement-to-target-animal-health-market 2025-03-27T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northstrive-biosciences-expands-licensing-agreement-to-target-animal-health-market 2025-03-27T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-of-80-therapies-advancing-for-chronic-kidney-disease-treatment-in-2025 2025-03-27T04:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-pipeline-of-80-therapies-advancing-for-chronic-kidney-disease-treatment-in-2025 2025-03-27T04:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/drug-shortages-crisis-causes-impacts-and-solutions-in-the-us-healthcare-system 2025-03-27T04:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-shortages-crisis-causes-impacts-and-solutions-in-the-us-healthcare-system 2025-03-27T04:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/kalvista-completes-enrollment-in-pediatric-hae-trial-for-oral-therapy-sebetralstat 2025-03-27T02:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kalvista-completes-enrollment-in-pediatric-hae-trial-for-oral-therapy-sebetralstat 2025-03-27T02:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-advances-synthetic-lethality-pipeline-with-promising-preclinical-data-at-aacr-2025 2025-03-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryvu-therapeutics-advances-synthetic-lethality-pipeline-with-promising-preclinical-data-at-aacr-2025 2025-03-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/dyadic-international-reports-strong-2024-performance-with-1-9-million-in-milestone-and-license-revenue 2025-03-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyadic-international-reports-strong-2024-performance-with-1-9-million-in-milestone-and-license-revenue 2025-03-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/alcon-acquires-majority-stake-in-aurion-biotech-to-advance-first-ever-corneal-cell-therapy 2025-03-26T23:32:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcon-acquires-majority-stake-in-aurion-biotech-to-advance-first-ever-corneal-cell-therapy 2025-03-26T23:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-secures-global-license-for-novel-prmt5-inhibitor-targeting-mtap-deleted-tumors 2025-03-26T23:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-secures-global-license-for-novel-prmt5-inhibitor-targeting-mtap-deleted-tumors 2025-03-26T23:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-phase-ii-jaspis-01-trial-of-dapolsertib-for-relapsed-refractory-dlbcl 2025-03-26T22:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-ii-jaspis-01-trial-of-dapolsertib-for-relapsed-refractory-dlbcl 2025-03-26T22:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/chosa-s-platinum-drug-response-predictor-shows-promise-in-personalizing-cancer-treatment 2025-03-26T22:34:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chosa-s-platinum-drug-response-predictor-shows-promise-in-personalizing-cancer-treatment 2025-03-26T22:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/rani-therapeutics-achieves-bioequivalence-with-oral-glp-1-glp-2-dual-agonist-for-obesity-treatment 2025-03-26T22:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rani-therapeutics-achieves-bioequivalence-with-oral-glp-1-glp-2-dual-agonist-for-obesity-treatment 2025-03-26T22:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-treatment-for-insatiable-hunger-in-prader-willi-syndrome 2025-03-26T22:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-treatment-for-insatiable-hunger-in-prader-willi-syndrome 2025-03-26T22:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-treatment-for-hyperphagia-in-prader-willi-syndrome 2025-03-26T22:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-treatment-for-hyperphagia-in-prader-willi-syndrome 2025-03-26T22:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/medrio-unveils-enhanced-rtsm-solution-to-accelerate-clinical-trial-implementation 2025-03-26T22:32:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medrio-unveils-enhanced-rtsm-solution-to-accelerate-clinical-trial-implementation 2025-03-26T22:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/microplastics-exposure-linked-to-higher-rates-of-cardiovascular-disease-and-diabetes-in-coastal-communities 2025-03-26T20:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microplastics-exposure-linked-to-higher-rates-of-cardiovascular-disease-and-diabetes-in-coastal-communities 2025-03-26T20:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-reports-strong-financial-results-and-pipeline-progress-in-2024 2025-03-26T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose-immunotherapeutics-reports-strong-financial-results-and-pipeline-progress-in-2024 2025-03-26T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/vaximm-s-vxm01-avelumab-combination-shows-promise-in-phase-2a-glioblastoma-trial 2025-03-26T19:33:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaximm-s-vxm01-avelumab-combination-shows-promise-in-phase-2a-glioblastoma-trial 2025-03-26T19:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/nitisinone-shows-promise-as-novel-malaria-control-strategy-by-making-human-blood-lethal-to-mosquitoes 2025-03-26T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nitisinone-shows-promise-as-novel-malaria-control-strategy-by-making-human-blood-lethal-to-mosquitoes 2025-03-26T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/uveitis-and-optic-neuritis-markets-set-for-major-growth-through-2034-as-new-therapies-advance 2025-03-26T19:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uveitis-and-optic-neuritis-markets-set-for-major-growth-through-2034-as-new-therapies-advance 2025-03-26T19:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/anhorn-medicines-initiates-phase-i-trial-of-novel-protein-degrader-for-hair-loss 2025-03-26T19:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anhorn-medicines-initiates-phase-i-trial-of-novel-protein-degrader-for-hair-loss 2025-03-26T19:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/nanoscope-s-optogenetic-gene-therapy-shows-promise-in-retinitis-pigmentosa-clinical-trials 2025-03-26T19:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoscope-s-optogenetic-gene-therapy-shows-promise-in-retinitis-pigmentosa-clinical-trials 2025-03-26T19:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-s-ko-2806-shows-promise-in-combination-therapy-for-renal-cell-carcinoma 2025-03-26T17:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-s-ko-2806-shows-promise-in-combination-therapy-for-renal-cell-carcinoma 2025-03-26T17:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-rules-generic-drugmakers-can-deduct-hatch-waxman-litigation-expenses 2025-03-26T17:33:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-rules-generic-drugmakers-can-deduct-hatch-waxman-litigation-expenses 2025-03-26T17:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/nuvectis-pharma-to-present-promising-nxp900-data-at-2025-aacr-meeting 2025-03-26T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvectis-pharma-to-present-promising-nxp900-data-at-2025-aacr-meeting 2025-03-26T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/epicrispr-biotechnologies-secures-68-million-to-advance-first-epigenetic-therapy-for-fshd 2025-03-26T16:40:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epicrispr-biotechnologies-secures-68-million-to-advance-first-epigenetic-therapy-for-fshd 2025-03-26T16:40:43+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-s-wrn-inhibitor-ide275-shows-promise-for-msi-h-cancers-featured-in-aacr-2025-oral-presentation 2025-03-26T16:38:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-s-wrn-inhibitor-ide275-shows-promise-for-msi-h-cancers-featured-in-aacr-2025-oral-presentation 2025-03-26T16:38:54+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-to-present-pivotal-breast-cancer-immunotherapy-data-at-aacr-2025 2025-03-26T16:38:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briacell-to-present-pivotal-breast-cancer-immunotherapy-data-at-aacr-2025 2025-03-26T16:38:53+00:00 hourly 0.9 https://trial.medpath.com/news/over-220-pipeline-therapies-in-development-for-non-hodgkin-s-lymphoma-reports-delveinsight 2025-03-26T16:37:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/over-220-pipeline-therapies-in-development-for-non-hodgkin-s-lymphoma-reports-delveinsight 2025-03-26T16:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/ema-evaluating-fast-track-status-for-intrathecal-zolgensma-in-spinal-muscular-atrophy 2025-03-26T16:37:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-evaluating-fast-track-status-for-intrathecal-zolgensma-in-spinal-muscular-atrophy 2025-03-26T16:37:43+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-halts-natco-pharma-s-generic-risdiplam-launch-in-roche-patent-dispute 2025-03-26T16:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-halts-natco-pharma-s-generic-risdiplam-launch-in-roche-patent-dispute 2025-03-26T16:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/wave-life-sciences-to-seek-fda-approval-for-duchenne-muscular-dystrophy-drug-following-promising-phase-2-results 2025-03-26T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wave-life-sciences-to-seek-fda-approval-for-duchenne-muscular-dystrophy-drug-following-promising-phase-2-results 2025-03-26T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/medicenna-to-present-mdna11-ability-1-trial-update-and-novel-mdna113-data-at-aacr-2025 2025-03-26T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicenna-to-present-mdna11-ability-1-trial-update-and-novel-mdna113-data-at-aacr-2025 2025-03-26T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/lutris-pharma-to-present-phase-2-results-of-novel-b-raf-inhibitor-for-egfr-inhibitor-induced-skin-rash-at-aacr-2025 2025-03-26T16:36:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lutris-pharma-to-present-phase-2-results-of-novel-b-raf-inhibitor-for-egfr-inhibitor-induced-skin-rash-at-aacr-2025 2025-03-26T16:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-reports-78-reduction-in-sleep-disturbances-with-igc-ad1-in-alzheimer-s-phase-2-trial 2025-03-26T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-reports-78-reduction-in-sleep-disturbances-with-igc-ad1-in-alzheimer-s-phase-2-trial 2025-03-26T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/diaceutics-secures-ps11-5m-contract-with-partner-therapeutics-to-commercialize-oncology-precision-medicine-bizengri 2025-03-26T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diaceutics-secures-ps11-5m-contract-with-partner-therapeutics-to-commercialize-oncology-precision-medicine-bizengri 2025-03-26T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/cytosite-bio-partners-with-lantheus-to-develop-granzyme-b-pet-imaging-for-real-time-immunotherapy-monitoring 2025-03-26T16:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytosite-bio-partners-with-lantheus-to-develop-granzyme-b-pet-imaging-for-real-time-immunotherapy-monitoring 2025-03-26T16:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-inflammatory-response-varies-significantly-across-pandemic-waves-study-of-8614-patients-reveals 2025-03-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-inflammatory-response-varies-significantly-across-pandemic-waves-study-of-8614-patients-reveals 2025-03-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avalo-therapeutics-advances-il-1b-antibody-in-phase-2-trial-for-hidradenitis-suppurativa-with-promising-market-potential 2025-03-26T13:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalo-therapeutics-advances-il-1b-antibody-in-phase-2-trial-for-hidradenitis-suppurativa-with-promising-market-potential 2025-03-26T13:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-to-present-novel-cancer-therapies-abbv-969-and-abbv-514-at-aacr-annual-meeting-2025 2025-03-26T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-to-present-novel-cancer-therapies-abbv-969-and-abbv-514-at-aacr-annual-meeting-2025 2025-03-26T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/knight-therapeutics-launches-minjuvi-for-relapsed-refractory-dlbcl-in-mexico 2025-03-26T13:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/knight-therapeutics-launches-minjuvi-for-relapsed-refractory-dlbcl-in-mexico 2025-03-26T13:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-approvable-letter-for-nyxoah-s-genio-system-for-obstructive-sleep-apnea 2025-03-26T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-approvable-letter-for-nyxoah-s-genio-system-for-obstructive-sleep-apnea 2025-03-26T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-winrevair-shows-promising-phase-3-results-for-pulmonary-arterial-hypertension-treatment 2025-03-26T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-winrevair-shows-promising-phase-3-results-for-pulmonary-arterial-hypertension-treatment 2025-03-26T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-to-showcase-novel-adc-technologies-targeting-gastrointestinal-cancers-at-aacr-2025 2025-03-26T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-to-showcase-novel-adc-technologies-targeting-gastrointestinal-cancers-at-aacr-2025 2025-03-26T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-seeks-nysdoh-approval-for-novel-h5-bird-flu-diagnostic-test 2025-03-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-dna-sciences-seeks-nysdoh-approval-for-novel-h5-bird-flu-diagnostic-test 2025-03-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cypath-r-lung-demonstrates-clinical-impact-in-real-world-lung-cancer-detection-cases 2025-03-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cypath-r-lung-demonstrates-clinical-impact-in-real-world-lung-cancer-detection-cases 2025-03-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/supira-medical-raises-120m-in-series-e-funding-completes-support-i-enrollment-for-novel-cardiac-support-device 2025-03-26T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supira-medical-raises-120m-in-series-e-funding-completes-support-i-enrollment-for-novel-cardiac-support-device 2025-03-26T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-secures-ps434083-investment-to-launch-gene-therapy-trial-in-aged-dogs 2025-03-26T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genflow-biosciences-secures-ps434083-investment-to-launch-gene-therapy-trial-in-aged-dogs 2025-03-26T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/gv20-therapeutics-partners-with-mitsubishi-tanabe-to-develop-novel-ai-discovered-antibody-drug-conjugates 2025-03-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gv20-therapeutics-partners-with-mitsubishi-tanabe-to-develop-novel-ai-discovered-antibody-drug-conjugates 2025-03-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-si-launches-platinum-pro-protein-sequencer-to-advance-drug-development-and-proteomics-research 2025-03-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-si-launches-platinum-pro-protein-sequencer-to-advance-drug-development-and-proteomics-research 2025-03-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aligos-therapeutics-reports-promising-96-week-data-for-hbv-treatment-and-positive-results-in-mash-study-at-apasl-2025 2025-03-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aligos-therapeutics-reports-promising-96-week-data-for-hbv-treatment-and-positive-results-in-mash-study-at-apasl-2025 2025-03-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-sanofi-s-mrna-chlamydia-vaccine-candidate 2025-03-26T07:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-sanofi-s-mrna-chlamydia-vaccine-candidate 2025-03-26T07:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/israel-unveils-streamlined-drug-approval-process-to-accelerate-patient-access 2025-03-26T07:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/israel-unveils-streamlined-drug-approval-process-to-accelerate-patient-access 2025-03-26T07:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/hydroxychloroquine-shows-promise-as-pretreatment-for-til-cancer-therapy-juncell-therapeutics-reports 2025-03-26T06:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydroxychloroquine-shows-promise-as-pretreatment-for-til-cancer-therapy-juncell-therapeutics-reports 2025-03-26T06:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/penn-researchers-develop-safe-dna-delivery-system-using-lipid-nanoparticles-for-chronic-disease-treatment 2025-03-26T04:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-researchers-develop-safe-dna-delivery-system-using-lipid-nanoparticles-for-chronic-disease-treatment 2025-03-26T04:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-provides-positive-feedback-on-pleco-s-ptx-252-for-acute-myeloid-leukemia-treatment 2025-03-26T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-provides-positive-feedback-on-pleco-s-ptx-252-for-acute-myeloid-leukemia-treatment 2025-03-26T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alarming-rise-in-heart-related-maternal-deaths-in-the-us-study-finds 2025-03-26T02:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alarming-rise-in-heart-related-maternal-deaths-in-the-us-study-finds 2025-03-26T02:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacy-deserts-and-biosimilar-adoption-reshape-managed-care-landscape 2025-03-26T02:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacy-deserts-and-biosimilar-adoption-reshape-managed-care-landscape 2025-03-26T02:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-invests-2-billion-in-chinese-triple-g-weight-loss-treatment 2025-03-26T01:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-invests-2-billion-in-chinese-triple-g-weight-loss-treatment 2025-03-26T01:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-unveils-promising-preclinical-data-for-five-oncology-drug-candidates-at-aacr-2025 2025-03-26T01:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-unveils-promising-preclinical-data-for-five-oncology-drug-candidates-at-aacr-2025 2025-03-26T01:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-launches-dinomite-trial-testing-papaverine-to-enhance-radiation-therapy-in-rectal-cancer 2025-03-26T01:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-launches-dinomite-trial-testing-papaverine-to-enhance-radiation-therapy-in-rectal-cancer 2025-03-26T01:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/divitum-r-tka-blood-test-shows-promise-in-predicting-immunotherapy-response-across-multiple-cancers 2025-03-26T00:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/divitum-r-tka-blood-test-shows-promise-in-predicting-immunotherapy-response-across-multiple-cancers 2025-03-26T00:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-spot-mas-becomes-asia-s-first-clinically-validated-multi-cancer-blood-test 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-solutions-spot-mas-becomes-asia-s-first-clinically-validated-multi-cancer-blood-test 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-develops-pan-kras-inhibitor-amg-410-to-target-broader-range-of-kras-mutant-tumors 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-develops-pan-kras-inhibitor-amg-410-to-target-broader-range-of-kras-mutant-tumors 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-to-showcase-six-novel-cancer-therapeutics-at-2025-aacr-annual-meeting 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-to-showcase-six-novel-cancer-therapeutics-at-2025-aacr-annual-meeting 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-of-200-therapies-targets-colorectal-cancer-treatment-landscape 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-pipeline-of-200-therapies-targets-colorectal-cancer-treatment-landscape 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bcg-revaccination-fails-to-prevent-tuberculosis-infection-in-large-phase-2b-trial 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bcg-revaccination-fails-to-prevent-tuberculosis-infection-in-large-phase-2b-trial 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lunit-and-astrazeneca-to-present-ai-model-for-egfr-mutation-prediction-in-nsclc-at-aacr-2025 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunit-and-astrazeneca-to-present-ai-model-for-egfr-mutation-prediction-in-nsclc-at-aacr-2025 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-achieves-first-myeloma-car-t-treatment-using-mainland-manufactured-therapy 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-achieves-first-myeloma-car-t-treatment-using-mainland-manufactured-therapy 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nouscom-s-nous-209-shows-promising-results-in-cancer-interception-for-lynch-syndrome-patients 2025-03-25T22:35:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nouscom-s-nous-209-shows-promising-results-in-cancer-interception-for-lynch-syndrome-patients 2025-03-25T22:35:47+00:00 hourly 0.9 https://trial.medpath.com/news/aulos-bioscience-to-present-promising-phase-2-data-for-novel-il-2-therapeutic-in-melanoma-treatment 2025-03-25T22:35:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aulos-bioscience-to-present-promising-phase-2-data-for-novel-il-2-therapeutic-in-melanoma-treatment 2025-03-25T22:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/belay-diagnostics-and-genomoncology-partner-to-enhance-cns-cancer-liquid-biopsy-testing 2025-03-25T22:35:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belay-diagnostics-and-genomoncology-partner-to-enhance-cns-cancer-liquid-biopsy-testing 2025-03-25T22:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-blujepa-first-novel-oral-antibiotic-for-utis-in-over-two-decades 2025-03-25T22:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-blujepa-first-novel-oral-antibiotic-for-utis-in-over-two-decades 2025-03-25T22:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-egrifta-wrtm-new-weekly-reconstitution-formulation-for-hiv-associated-lipodystrophy 2025-03-25T22:34:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-egrifta-wrtm-new-weekly-reconstitution-formulation-for-hiv-associated-lipodystrophy 2025-03-25T22:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/relmada-therapeutics-secures-licensing-for-novel-bladder-cancer-treatment-ndv-01 2025-03-25T20:33:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relmada-therapeutics-secures-licensing-for-novel-bladder-cancer-treatment-ndv-01 2025-03-25T20:33:55+00:00 hourly 0.9